Skip to main content
PMC home page
Frontiers in Genetics logoLink to Frontiers in Genetics
. 2023 Feb 24;14:1110656. doi: 10.3389/fgene.2023.1110656

From Basic Science to Clinical Practice: The Role of Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A)/p90 in Cancer

Beibei Chen 1,2, Huihui Hu 1,2, Xiaobing Chen 1,2,*
PMCID: PMC9998691  PMID: 36911405

Abstract

Cancerous inhibitor of protein phosphatase 2A (CIP2A), initially reported as a tumor-associated antigen (known as p90), is highly expressed in most solid and hematological tumors. The interaction of CIP2A/p90, protein phosphatase 2A (PP2A), and c-Myc can hinder the function of PP2A toward c-Myc S62 induction, thus stabilizing c-Myc protein, which represents a potential role of CIP2A/p90 in tumorigeneses such as cell proliferation, invasion, and migration, as well as cancer drug resistance. The signaling pathways and regulation networks of CIP2A/p90 are complex and not yet fully understood. Many previous studies have also demonstrated that CIP2A/p90 can be used as a potential therapeutic cancer target. In addition, the autoantibody against CIP2A/p90 in sera may be used as a promising biomarker in the diagnosis of certain types of cancer. In this Review, we focus on recent advances relating to CIP2A/p90 and their implications for future research.

Keywords: CIP2A/p90, cancer, tumor-associated antigen (TAA), signaling pathways, biomarker, prognosis

1 Introduction

The sera of patients diagnosed with cancer contain antibodies that can react with a unique group of autologous cellular proteins called tumor-associated antigens (TAAs) (Chen et al., 2018). The immune system of cancer patients is a sensor of alterations in the structure and/or function of participants in tumorigenesis pathways and is capable of immune responses in the form of autoantibodies against these TAAs (Jhunjhunwala et al., 2021). Circulating autoantibodies have been used as ’probes’ in cancer patients to isolate TAAs, which have been shown to be cellular factors participating in known tumorigenesis pathways (Tan, 2001; Tan and Zhang, 2008; Zhang et al., 2022). The constitution of TAAs do not include all cellular antigens identified by autoantibodies in cancer sera as some autoantibodies may exist in conditions that pre-date malignancy. Thus, many approaches aimed at identifying and characterizing authentic TAAs have been identified by anti-TAA autoantibodies, which can be used as biomarkers for diagnosis or early detection only after extensive evaluation with cancer and non-cancer sera (Zhang and Tan, 2010; Li et al., 2021).

CIP2A was initially identified as a TAA and was named p90 due to its molecular weight of 90 kDa (Soo Hoo et al., 2002). Autoantibodies against p90 were found in 21% of sera from a group of patients with liver cancer. Sera with anti-p90 localized to the cytoplasm were detected by indirect immunofluorescent staining in fetal mouse liver but not in adult liver (Zhang et al., 2002). Full-length cDNA encoding p90 was successfully isolated from a T24 expression library, including a sequence coding for a 905-amino-acid protein, predicted to have a molecular mass of 102 kDa. In a subsequent study, p90 was found to be identical to cancerous inhibitor of protein phosphatase2A (CIP2A) by a research group from Finland (Junttila et al., 2007). The function of CIP2A/p90 is related to its binding with c-Myc and inhibiting dephosphorylation of S62 caused by PP2A (Farrington et al., 2020).

Many studies have focused on the function of CIP2A/p90 since the protein was identified by our study group. This review focuses on recent advances, which have primarily been associated with the determination of CIP2A/p90 function or its potential as a biomarker for the early detection of various types of cancer.

2 The function of CIP2A/p90 in cancers

Protein kinase phosphorylation and protein phosphatase (PP) dephosphorylation are considered the most common mechanisms involved in intracellular protein regulation and signal transduction. Their imbalance is associated with cystic fibrosis, Alzheimer’s disease (AD), and other diseases, such as cancer (Ruvolo, 2019; Shentu et al., 2019; Mercier et al., 2020; Khan M M et al., 2021; Vainonen et al., 2021). According to the dephosphorylated amino acid residues, PP has been categorized into two families, the protein tyrosine phosphatase family and the serine threonine phosphatase family. PP2A is a widely conserved serine threonine phosphatase and has been defined as a kind of tumor suppressor protein (Chen et al., 2013; Perrotti and Neviani, 2013). PP2A is a trimeric holoenzyme, with a scaffold A subunit, a catalytic C subunit, and several different regulatory B subunits. The B subunits determine the subcellular localization and substrate specificity of the PP2A holoenzyme (Ruvolo, 2016). Although PP2A has multiple substrates, its anti-cancer function is mostly related to the dephosphorylation and stabilization of c-Myc (Pippa and Odero, 2020). Recent studies had shown that PP2A is widely involved in the regulation of cellular physiological and pathological processes, such as energy metabolism, cell cycle, DNA replication, proliferation, apoptosis, and inflammatory responses (Sangodkar et al., 2016; Baskaran and Velmurugan, 2018; Kauko and Westermarck, 2018; Remmerie and Janssens, 2019; Khan R et al., 2021). C-Myc is overexpressed in most cancers as a transcription factor with oncogenic capability that mediates cell proliferation, apoptosis, differentiation, adhesion, migration, metabolism, and DNA replication (Sun and Gao, 2017; Duffy et al., 2021; Dhanasekaran et al., 2022; Grieb and Eischen, 2022). As mentioned earlier, CIP2A, encoded by the KIAA1524 gene located on human chromosome 3q13.13, is a major endogenous PP2A-inhibiting protein. The interaction among CIP2A/p90, PP2A, and c-Myc can hinder the function of PP2A toward c-Myc S62 induction and therefore stabilize c-Myc protein, which represents a potential role of CIP2A/p90 in the promotion of cancer (Pippa and Odero, 2020; Scarpa et al., 2021).

CIP2A/p90 plays an important role in the proliferation, apoptosis, invasion, migration, epithelial–mesenchymal transition (EMT), cell cycle, and drug resistance of different tumor cells. CIP2A/p90 was overexpressed in 65%–90% of tissues in almost all human cancers, and this has been associated with poor survival (Tarek et al., 2021). The molecular mechanism of CIP2A/p90 in cancer has mostly been associated with the interaction among CIP2A/p90, PP2A, and c-Myc (Table 1). On the other hand, several studies have indicated that the silencing of CIP2A/p90 by small interfering RNAs (siRNA) inhibited the growth of xenografted tumors of various kinds of cancer cells (Table 1).

TABLE 1.

siRNA downregulates CIP2A on tumor cells and potential molecular mechanisms.

Type of cancer Cell lines Proliferation Apoptosis Invasion Migration EMT Cell cycle Drug resistance Potential molecular mechanisms References
Head and neck squamous cell cancer (HNSCC) UT-SCC-7 ↓ a — b — — — — — c-Myc ↓ Junttila et al. (2007)
UT-SCC-9
CAL27, FaDu ↓ ↑ d — — — — — Axin2 ↓, MMP7 ↓, c-Myc ↓ Kleszcz et al. (2019)
Nasopharyngeal carcinoma (NPC) CNE-2, SUNE-1 ↓ — — — — — — c-Myc ↓ Liu et al. (2014a)
Neuroblastoma SK-N-AS, SK-N-BE, SH-EP, WAC2 — — — ↓ — — — — Williams et al. (2019)
Oral cancer NCI-60 ↓ — ↓ ↓ — — — c-Myc ↓ Jung et al. (2013)
SCC-25 ↓ — — — — — — — Cantini et al. (2013)
Non-small-cell lung cancer (NSCLC) H1299 ↓ — ═ c — — — — AKT-mTOR signaling pathway Dong et al. (2011); Lei et al. (2014)
L78 ↓ — — — — — — — Ma et al. (2011)
SPCA1 ↓ — — — — — ↓(Cisplatin) AKT signaling pathway Ma et al. (2011); Wei et al. (2014)
A549 ↓ — ═ — — — ↓(Cisplatin) AKT signaling pathway Dong et al. (2011); Ma et al. (2011); Wei et al. (2014)
Breast cancer MDA-MB-231 ↓ — ↓ — — ↓ — PP2A/c-Myc/p27Kip1 signaling pathway Xing et al. (2016); Liu et al. (2017b)
BT549
MCF-7/ADR ↓ ↑ — — — — — — Zhu and Wei (2021)
Esophageal squamous cell cancer EC109 ↓ ↑ — — — ═ — c-Myc ↓ Qu et al. (2012)
Gastric cancer MKN-28 ↓ — — — — — — c-Myc ↓ Khanna et al. (2009)
KATOIII
SGC7901/DDP ↓ ↑ — — — — ↓(Cisplatin) — Ji et al. (2018)
Hepatocellular carcinoma (HCC) Hep3B ↓ ↑ — — — ↓ — CDK2↓, CDK4↓ Yang et al. (2018)
HepG2 Cyclin D1↓
SMMC-7721
BEL-7402
MHCC97H ↓ — ↓ ↓ — — — — Li et al. (2022)
SNU387
Colon cancer Caco-2 ↓ — — — — — — ERK ↓ Chen J.S et al. (2015)
HCT116 ↓ — — — — — — c-Myc ↓ Wiegering et al. (2013)
HT29 ↓ — — — — — ↓(5-fluorouracil, oxaliplatin, SN38) — Teng et al. (2012)
HCT116 SW480 ↓ — — — — ↓ — — Denk et al. (2021)
LS174t
Pancreatic cancer SW1990 ↓ — — — — — ↓(Gemcitabine) BCL2 ↓, AKT ↓ Xu et al. (2016)
Clear cell renal cancer 786-O — — ↓ — ↓ — — — Tang et al. (2015)
A498 ═ — ↓ ↓ — — — c-Myc ↓ Ren et al. (2011)
KRC/Y
Caki-1 ↓ — — — — — — AKT signaling pathway Gao et al. (2020)
Prostate cancer LNCaP ↓ — — — — — — — Khanna et al. (2015)
PC-3 — — — — — ↓ — CIP2A interacts with Sgol1 Pallai et al. (2015)
C4-2 ↓ — — — — — ↓(Cabazitaxel) — Huang et al. (2015)
Bladder cancer T24 ↓ ↑ ↓ ↓ ↓ — — — Xue et al. (2013); Pang et al. (2016)
Cervical cancer HeLa ↓ — — — ↓ — ↓(Doxorubicin, cisplatin, and paclitaxel) c-Myc ↓, Pgp ↓, MEK/ERK signaling pathway (CIP2A interacts with H-Ras) Liu W et al. (2011); Wu et al. (2015); Liu J et al. (2016)
Endometrioid adenocarcinoma (EAC) SiHa ↓ — — — — — — c-Myc ↓ Liu J et al. (2011)
Caski
Ishikawa ↓ ↑ ↓ ↓ — ↓ — c-Myc ↓, Cyclin D1↓ Yu et al. (2018)
An3ca ↓ — ↓ ↓ — ↓ — c-Myc ↓, Cyclin D1↓ Yu et al. (2018)
Ovarian cancer SKOV3DDP ↓ — — — — — ↓(Cisplatin) AKT signaling pathway Zhang et al. (2015)
A2780, SKOV3 ↓ — — — — ↓ ↓(Paclitaxel) Cyclin D1 ↓, c-Myc ↓, p-Rb ↓, Bcl-2 ↓, p-AKT ↓ Fang et al. (2012)
Astrocytoma A172 ↓ ↑ — — — — — c-Myc ↓, pAKT ↓, BCL2 ↓ Yi et al. (2013)
U87
Melanoma FEMX1, WM1366, WM983b, WM9 ↓ ↑ — — — — — PI3K/AKT signaling pathway Flørenes et al. (2015)
A375 — — ↓ ↓ — — — — Shi et al. (2014)
Osteosarcoma MG-63 ↓ — ↓ — — — — c-Myc ↓, pAKT ↓ Zhai et al. (2014)
Glioblastoma U251MG, WK1 ↓ — — — — — — — Khanna et al. (2020)
Colorectal cancer DLD1, HT29 ↓ ↑ — — — — — c-Myc ↓ Chen et al. (2020)
Multiple myeloma (MM) RPMI-8226, NCI-H929 ↓ ↑ — — — — — c-Myc ↓, PI3K/AKT/mTOR signaling pathway Yang et al. (2016); Zheng et al. (2016)
Acute myeloid leukemia (AML) HEL ↓ — — — — — — c-Myc ↓ Barragán et al. (2015)
HL60 ↓ — — — — — — — Wang et al. (2011)
Chronic myelocytic leukemia (CML) K562 ↓ ↑ — — — — — c-Myc ↓ Wang H. W et al. (2014)
Open in a new tab
a

Inhibition or downregulation.

b

Unknown.

c

No significant effect.

d

Promotion or upregulation.

As shown in Table 1, silencing CIP2A/p90 with siRNA can further reduce the expression of c-Myc to inhibit cell proliferation and induce cell apoptosis (Yang et al., 2016; Zheng et al., 2016). In addition, siRNA inhibition of CIP2A transcription can make colorectal cancer cells sensitive to radiation and reduce their survival rate in vitro (Birkman et al., 2018). CIP2A/p90 can promote p27Kip1 phosphorylation at Ser10 by via inhibiting Akt-associated PP2A activity, which seems to relocalize p27Kip1 to the cytoplasm. On the other hand, CIP2A/p90 can also recruit c-Myc to mediate the transcriptional inhibition of p27Kip1 and induce cell cycle arrest at the G2/M phase (Liu H et al., 2017). In addition, in cells expressing human papillomavirus 16 oncoprotein E6, it can promote the transformation of the G1/S cell cycle through B-Myb (Tian et al., 2018). Furthermore, several studies have shown that CIP2A/P90 regulates STAT3 phosphorylation and IL-17 expression in Th17 cells by regulating the intensity of interaction between AGK and STAT3 (Chen et al., 2013; Khan et al., 2020a; Khan et al., 2020b). However, only a few studies on the molecular mechanism of the CIP2A/p90 regulating function are mentioned aboved. CIP2A/p90 also has a PP2A-independent function, which can directly interact with Polo-like kinase1 (PLK1) but not with mitosis gene A-related kinase 2 (NEK2), H-Ras, etc., to regulate cellular function. CIP2A/p90 can interact with PLK1 and enhance the stability and activity of PLK1, thereby promoting mitosis in human cancer cells (Kim et al., 2013). The depletion of CIP2A/p90 may also prolong cell division time. CIP2A/p90 interacts with NEK2 during the G2/M phase, and can facilitate centrosome separation and mitotic spindle dynamics in cell cycle progression (Jeong et al., 2014). CIP2A/p90, in association with the oncogene H-Ras and through the recruitment of the MEK/ERK signaling pathway and c-Myc dephosphorylation by PP2A, is required for EMT in the progression of cancer (Wu et al., 2015). Patients with both HOXB13 T and CIP2A T alleles have a higher risk of prostate cancer and invasive disease, earlier biochemical recurrence, and lower disease-specific life expectancy. HOXB13 protein binding to the CIP2A gene can functionally promote CIP2A transcription (Sipeky et al., 2018). Studies have confirmed that CIP2A is an essential gene in BRCA1 and BRCA2 mutant cells, finding that the CIP2A-TOPBP1 axis can protect chromosome stability, which is a synthetic lethal target for BRCA mutant cancer (Adam et al., 2021).

3 The signaling pathways and regulation network of CIP2A/p90

The regulation network of CIP2A/p90 was established through direct interactions of CIP2A/p90 or indirectly through interactions of CIP2A/PP2A with either multiple key cellular proteins/transcription factors or with oncogenic signaling pathways. Figure 1 shows the signaling pathways and regulation mechanisms mainly associated with CIP2A/p90.

FIGURE 1.

FIGURE 1

Open in a new tab

The signaling pathways and regulation networks of CIP2A/p90. Several signaling pathways, including the PI3K–AKT–mTOR pathway, the RAS–MEK–ERK pathway, the Wnt–β-catenin pathway, the MKK4/MKK7-JNK-c-Jun pathway, the p53-p21-E2F1-CIP2A/p90 pathway, and the phosphorylation and degradation of c-Myc, non-coding RNAs, and other regulation factors, such as Oct4, AFT2, CHK1, and HDAC1, are included in this figure. Bidirectional blue arrows indicate interactions between two entities; unidirectional blue arrows indicate a positive influence of an entity on another; red lines indicate a negative influence of one entity on another.

3.1 The PI3K–AKT–mTOR pathway

Phosphatidylinositol 3-kinase (PI3K) is a heterodimer consisting of a regulatory subunit (p85) and a catalytic subunit (p110). Activated PI3K can convert phosphatidylinositol 4,5-bisphosphate (PIP2) to PIP3, which is a second messenger through 3-phosphoinositide-dependent kinase1 (PDK1), indirectly activates AKT. The activated AKT acts on a variety of substrates, such as mTOR and glycogen synthase kinase-3β (GSK-3β), to regulate cell growth, proliferation, and other functions (Vogelstein et al., 2013). IL-10 phosphorylates cAMP response element-binding protein (CREB) through the PI3K/AKT signaling pathway, thereby regulating CIP2A/p90 gene expression (Sung et al., 2013). Based on our previous study, it was found that CIP2A/p90 can regulate AKT phosphorylation at S473 under growth factor stimulation. Our research also showed that CIP2A/p90 might promote cell proliferation through the AKT–mTOR signaling pathway (Lei et al., 2014). In addition, a new study further confirmed that the overexpression of CIP2A was a key contributory event of AKT phosphorylation in the correlation analysis of p-AKT and CIP2A in 220 clinical samples, and emphasized that the CIP2A-AKT axis is a promising therapeutic target for breast cancer (Luque et al., 2022).

3.2 The RAS–MEK–ERK pathway

Ras, which is stimulated by extracellular signals, recruits Raf to bind and activate it on the cell membrane. The activated Raf (MAPKKK) can reactivate MAPKK, which in turn activates extracellular protein kinases (ERKs) (also known as MAPK), and finally, the activated ERK can further activate a number of transcription factors, such as Elk-1, Ets1, ATF, NF-κB, and c-Myc, to trigger a variety of biological effects (De et al., 2014). Ets1, as the transcription factor, can mediate high CIP2A/p90 expression in human cancers through increased activity of the EGFR-MEK1/2-ERK pathway (Khanna et al., 2011). The binding of Ets1 and Elk1 together to the proximal CIP2A/p90 promoter is absolutely required for CIP2A/p90 expression in liver, endometrial, and cervical carcinoma cells (Pallai et al., 2012). Additionally, 17β-estradiol (E2) activates EGFR, thus stimulating the MEK1/2 and PI3K pathways and further increasing the expression of CIP2A/p90 through the MEK1/2-induced transcription factor Ets1 to enhance the proliferation of cancer cells (Choi et al., 2014).

3.3 The MKK4/MKK7-JNK-c-Jun pathway

JNK belongs to the mitogen-activated protein family (MAPK), which responds to certain stimuli, such as cytokines, UV radiation, heat, and osmotic shock. The activated JNK leads to cell migration, proliferation, and invasion in cancers. According to our research, we found that the overexpression of CIP2A/p90 is associated with increased JNK pathway through the phosphorylation of MKK4/MKK7-JNK-c-Jun signaling. However, the exact mechanism by which CIP2A/p90 modulates the JNK phosphorylation pathway is still unknown (Peng et al., 2015). Knockdown of CIP2A decreases JNK phosphorylation and the phosphorylation of downstream transcriptional factors ATF2 and c-Jun, the transcriptional activity of which is also decreased. Furthermore, the expression level of CIP2A also affects the phosphorylation of the upstream kinase of JNK, MKK4/MKK7 (Peng et al., 2015).

3.4 The P53-p21-E2F1-CIP2A/p90 pathway

The overexpression of E2F1 leads to activated cell cycle and uncontrolled cellular proliferation in the majority of human cancers. Owing to the inactivation of p53 or p21, the overexpression of E2F1 promotes the expression of oncoprotein CIP2A/p90, which in turn increases stabilizing serine 364 phosphorylation of E2F1. The p53-p21-Rb pathway can negatively regulate the activity of E2F1 transcription (Lucas et al., 2015). Furthermore, research has shown that the positive feedback loop of E2F1-CIP2A/p90 is very important to the sensitivity of senescence and growth arrest induction in breast and cervical cancer cells (Laine et al., 2013; Wang et al., 2017). The CIP2A-AKT-mTOR pathway controls cell growth, apoptosis, and autophagy. Polyphyllin I (PPI) and polyphyllin VII (PPVII) are natural components extracted from Paris polyphylla that have anticancer properties. Examination of the mechanism revealed that PPI and PPVII significantly upregulate p53, induce caspase-dependent apoptosis, and suppress the CIP2A-AKT-mTOR pathway. The activation of autophagy is mediated through PPI and PPVII, which induce the inhibition of mTOR (Feng F. et al., 2019).

3.5 Non-coding RNA

MicroRNA, with a length of 18–25 nucleotides, is a type of small single non-coding RNA that regulates gene post-transcriptional expression through binding with complementary sequences, which can degrade the target mRNA or inhibit its translation (Jung et al., 2013). miR-218 can bind to the 3'-UTR region of CIP2A/p90 in cutaneous melanoma cells to regulate the gene expression of CIP2A/p90. The upregulation of miR-218 inhibits the expression of CIP2A/p90 and meanwhile suppresses the functions of melanoma cells, such as migration, proliferation, invasion, and cell cycle (Lu et al., 2015). The study examined the effect of miR-218 on the expression of CIP2A in clear cell renal cell carcinoma (ccRCC). The results showed that the expression level of miR-218 in ccRCC was lower than that in adjacent non-tumor kidney tissues. The downregulation of CIP2A or the overexpression of miR-218 in ccRCC cells can inhibit cell proliferation and migration (Wei et al., 2019). miR-383-5p directly targets CIP2A/p90 to inhibit cell proliferation by G1 cell cycle phase arrest and promotes apoptosis in lung adenocarcinoma (Zhao et al., 2017). CIP2A/p90 is also targeted by miR-375, which stimulates the expression of p21 due to the promotion of its major transcriptional activator, p53, and consequently restrains the action of CIP2A/p90 and c-Myc in cell proliferation. These findings suggest that microRNA can act as a tumor suppressor of oncogenic elements, such as CIP2A/p90 (Jung et al., 2014). In addition, miR-548b-3p regulates proliferation, apoptosis, and mitochondrial function by targeting CIP2A in HCC (Lin and Wang, 2018). There is an automatic regulation feedback loop between CIP2A and miR-301a. Additionally, the feedback of miR-301a promotes the expression of CIP2A through ERK/CREB signal (Yin et al., 2019). A specificity protein 1 (SP1)-induced long non-coding RNA, DPPA2 upstream binding RNA (DUBR), upregulates CIP2A expression through E2F1-mediated transcription regulation, which also plays a role in upregulating CIP2A at the mRNA level by binding miR-520d-5p as a competing endogenous RNA (Liu et al., 2022). The knockdown of LINC00665 can also significantly decrease the cell proliferation, migration, and invasion of HCC, while overexpression of the short peptides of LINC00665 (CIP2A-BP) can markedly increase cell proliferation, invasion, and migration (Li et al., 2022).

3.6 Other regulation factors

The Wnt-β-catenin pathway: after the activation of Wnt, β-catenin is stabilized and bound to the T-cell factor (Tcf)/lymphoid enhancer factor (Lef) family transcription factors, thus leading to a transcriptional activation of target genes (Huang et al., 2019). Aberrant activation of the Wnt/β-catenin pathway is a common event in many types of cancers (Zhang and Wang, 2020). The upregulation of CIP2A/p90 might indirectly lead to reduced β-catenin levels via PP2A inactivation, reinforcing the polo-like kinases (Plk1)-dependent β-catenin inhibition (Li et al., 2015). Additionally, CIP2A/p90 enhances the stabilization of β-catenin to promote fibronectin-induced cancer cell proliferation (Gao et al., 2017).

Phosphorylation and degradation of c-Myc: ERK can phosphorylate c-Myc Ser62 to stabilize it. Then, GSK-3β further phosphorylates c-Myc Thr58, followed by prolyl isomerase (PIN-1), which can transform c-Myc (including both Ser62 and Thr58 phosphorylation sites) from a cis-structure to a trans-structure (Posternak and Cole, 2016). PP2A can catalyze the trans-structure of c-Myc Ser62 dephosphorylation to form the trans-structure of c-Myc (including the Thr58 phosphorylation site), which may be further ubiquitinated and degraded by protein ligase complex (containing FWB7) (Dang, 2012). CIP2A/p90 interacts directly with c-Myc and inhibits PP2A activity toward c-Myc Ser 62, thereby preventing c-Myc proteolytic degradation (Junttila et al., 2007).

Other regulation factors also exist. The expression of CIP2A/p90 in various tumor cells is regulated by other regulation factors with a certain complexity and cell specificity. Moreover, most of them are transcription factors. Octamer-binding transcription factor 4 (Oct4) positively regulates the expression of CIP2A/p90 both in embryonic stem cells and testicular cancer cell lines. The co-expression of Oct4 and CIP2A/p90 is also associated with the increased radio-resistance and aggressiveness in HNSCC cell lines (Ventelä et al., 2015). In addition, the study found that CIP2A can directly interact with TopBP1 and coordinate DNA damage-induced mitotic checkpoint and proliferation, thus driving the initiation and progression of basal breast cancer (Laine et al., 2021). In mouse embryonic fibroblasts, the transcription factor ATF2 binds to the AP-1 site in the promoter region of the CIP2A/p90 gene and initiates gene transcription (Mathiasen et al., 2012). Activated transcription factor 6 (ATF6) is one of the three major stress transduction factors of the endoplasmic reticulum and has been proven to promote chemotherapy resistance by changing the survival of cancer cells. Recent studies have shown that endoplasmic reticulum stress-related ATF6 upregulates CIP2A/p90, which helps to improve the prognosis of colon cancer (Liu X et al., 2018). The activity of checkpoint kinase 1 (CHK1) promotes the transcription of CIP2A/p90, thereby inhibiting the activity of PP2A, the tumor suppressor. In addition, the phosphorylation of CHK1 can upregulate the expression of the CIP2A/p90 gene through phosphorylation of serine 345 of CHK1 via DNA damage response kinases (DNA-PK) in human gastric cancer, ovarian cancer, colon cancer, and neuroblastoma (Khanna et al., 2013; Khanna et al., 2020). Histone deacetylase 1 (HDAC1) regulates CIP2A/p90 gene expression in colorectal cancer cells. The inhibition of HDAC1 by (S)-2 downregulated the transcription of CIP2A/p90 and unleashed PP2A activity, thereby inducing growth arrest and apoptosis in colorectal cancer cells (Balliu et al., 2016).

4 CIP2A/p90 expression and its clinical role in tumors

Compared with normal or para-cancerous tissues, CIP2A/p90 (protein or mRNA) is overexpressed or amplified at a high frequency in the vast majority of solid and hematological tumors (Tang et al., 2018). Recent studies have shown that the aberrant expression level of CIP2A/p90 is either significantly correlated with tumor stages or serves as a prognostic marker for overall survival (OS) and disease-free survival (DFS) (Table 2). According to numerous studies, the high expression of CIP2A/p90 in some cancers, such as cutaneous melanoma, breast cancer, colon cancer, cervical cancer, prostate cancer, and oral cancer, is associated with pathologic high-grade tumor and the progression of disease (Côme et al., 2009; Vaarala et al., 2010; Böckelman et al., 2011a; Böckelman et al., 2012; Shi et al., 2014; Velmurugan et al., 2019). As shown in our previous study, CIP2A/p90 is rarely expressed in non-cancerous/non-transformed cells, but is abundantly expressed in typically transformed cells (Soo Hoo et al., 2002).

TABLE 2.

Expression of CIP2A in various tumor tissues and its clinical significance.

Type of cancer Positive rate Relationship with survival rate Relationship with prognosis References
NPC 90.7% (254/280) + a + Liu et al. (2014b)
Tongue cancer 97.3% (71/73) + + Böckelman et al. (2011b)
Oral cancer 100% (133/133) + + Velmurugan et al. (2019)
Oral squamous cell carcinoma 54.3% (19/35) ± ± Alzahrani et al. (2020)
HNSCC 78.6% (11/14) - b - Junttila et al. (2007)
80.8% (42/52) + + Routila et al. (2016)
82.7% (43/52) + - Ventelä et al. (2015)
Thyroid carcinoma 85.3% (81/95) + + Chao et al. (2016)
Lung cancer 84.7% (61/72) - - Peng et al. (2015)
NSCLC 72.2% (65/90) + + Dong et al. (2011)
76.3% (74/97) + + Xu et al. (2012)
88.3% (184/209) + + Cha et al. (2017)
Breast cancer 39.4% (13/33) + - Côme et al. (2009)
35% (448/1280) + + Yu G et al. (2013)
46% (565/1228) - + Laine et al. (2013)
100% (46/46) - - Liu C. Y et al. (2014)
Esophageal squamous cell cancer 90% (36/40) - ×c Qu et al. (2012)
Esophageal adenocarcinoma 97.3% (110/113) × + Rantanen et al. (2013)
Gastric cancer 65% (145/223) + + Khanna et al. (2009)
67.6% (25/37) + + Chen F. F et al. (2015)
Esophagogastric junction adenocarcinoma 64.6% (42/65) + - Li et al. (2019)
Colorectal cancer 87.9% (661/752) × × Böckelman et al. (2012)
100% (167/167) + + Teng et al. (2012)
89.4% (93/104) + + Wiegering et al. (2013)
80.7% (21/26) + + Chen et al. (2020)
HCC 100% (136/136) + + He et al. (2012)
77.9% d (106/136) + + Huang C. Y et al. (2012)
Pancreatic cancer 56.3% (54/96) + + Wang et al. (2013)
70.8% (51/72) + + Xu et al. (2016)
Cholangiocarcinoma 78.9% (45/57) + + Xu et al. (2013)
Renal cancer 70.1% (75/107) + + Ren et al. (2011)
50.0% (55/110) + + Wang P et al. (2019)
73.7% d (59/80) - + Gao et al. (2020)
Bladder cancer 72.6% (85/117) + + Xue et al. (2013)
78.8% (63/80) - - Pang et al. (2016)
41.9% (18/43) - - Huang P et al. (2012)
Prostate cancer 72.9% (43/59) × × Vaarala et al. (2010)
96.2% (101/105) - × Celikden et al. (2020)
Cervical cancer 52.8% (38/72) - - Liu X et al. (2014)
60.8% (31/51) - - Wu et al. (2015)
Ovarian cancer 82.8% (434/524) + + Böckelman et al. (2011a)
65.8% (100/152) - - Fang et al. (2012)
Melanoma 100.0% (65/65) + + Shi et al. (2014)
Multiple myeloma 46.3% (19/41) - + Liu et al. (2017c)
Osteosarcoma 76.5% (39/51) - - Zhai et al. (2014)
AML 57.8% d (67/116) - - Wang et al. (2011)
100% d (203/203) + + Barragán et al. (2015)
CML 75.7% d (56/74) - - Wang J et al. (2014)
Open in a new tab
a

Related.

b

Unknown.

c

Unrelated.

d

CIP2A mRNA, positive rate (the rest was CIP2A protein positive rate).

As shown in Table 2, some controversial conclusions have been made in the same type of cancer by different research groups. Out of two studies (He et al., 2012; Huang C.Y et al., 2012), He et al. concluded that the high expression of CIP2A/p90 can predict poor outcome in patients with hepatocellular carcinoma, and therefore, this can be used as a significant prognostic factor for DFS and OS (He et al., 2012). Conversely, in the study by Huang et al., the expression of intratumoral CIP2A/p90 mRNA was not associated with prognosis, whereas non-cancerous CIP2A/p90 mRNA was shown to be an independent prognostic factor of OS and recurrence-free survival (RFS) (Huang L.P et al., 2012). Therefore, more extensive research evaluating both CIP2A/p90 protein and mRNA expression, with normal controls, is needed. As with hepatocellular carcinoma, the results from three investigations evaluating the prognostic value of CIP2A/p90 expression were contradictory (Böckelman et al., 2012; Teng et al., 2012; Wiegering et al., 2013). The investigations carried out by Wiegering et al. (2013) and Teng et al. (2012), examining 104 and 167 colon cancer specimens, respectively, both revealed that CIP2A/p90 expression is positively associated with prognosis. By contrast, Böckelman et al. (2012) analyzed 752 specimens and showed there was no significant association between CIP2A/p90 expression and prognosis. This disparity might be due to the different size of each sample or the different antibodies used for staining CIP2A/p90. In addition, the high expression of CIP2A/p90 has diagnostic significance in some cancers, such as papillary thyroid carcinoma, breast cancer, and chronic myeloid leukemia (Liu C Y et al., 2014; Chao et al., 2016; Xing et al., 2016; Clark et al., 2021).

5 Autoantibody to CIP2A/p90 as biomarker in cancers

As described above , CIP2A/p90 was initially isolated and characterized as a type of TAA (Soo Hoo et al., 2002). The immune system of certain cancer patients can recognize these aberrant TAA proteins as foreign antigens, thus producing antibodies, called autoantibodies in response. Therefore, anti-TAA autoantibodies might be regarded as biomarkers for the early detection of certain types of cancer (Tan, 2001; Tan and Zhang, 2008). According to our previous studies and others, the frequency of autoantibodies to CIP2A/p90 in sera is significantly higher than that of normal controls. When we selected a panel of TAAs, such as CIP2A/p90, the accumulative positive autoantibodies’ reactions in sera were much higher (Shi et al., 2005; Xie et al., 2011; Liu et al., 2014a). Some data showed the selected panel of TAAs had high specificity and sensitivity as immunodiagnostic biomarkers in both he test cohort and the validation cohort (Zhang et al., 2016; Hoshino et al., 2017). In addition, a few of the panel TAAs, including CIP2A/p90, had a high diagnostic performance in the detection of cancers, especially for the patients at early stage (Zhang et al., 2016; Wang X et al., 2019; Table 3).

TABLE 3.

Frequency of anti-CIP2A/p90 and the TAA panel in cancer patients and normal controls.

Cancer TAA panel number Percentage (number) of TAA positivity References
CIP2A/p90 Normal controls Panel Normal controls
Prostate 6 30.8% (41/133) 3.1% (3/96) 92.5% (122/133) 14.8% (14/96) Shi et al. (2005)
Prostate 6 - a - 79% (103/131) 16% (19/121) Xie et al. (2011)
Breast - 19.1% (32/168) 2.3% (2/88) - - Liu et al. (2014a)
Breast 5 - - 38% (147/386) - Sumazaki et al. (2021)
ESCC 4 - - 77.01% (499/648) b Zhang et al. (2016)
78.49% (292/372) c
Gastric cancer 6 8.0% (8/100) b 1.3% (1/79) b 49.0% (49/100) b 7.6% (6/79) b Hoshino et al. (2017)
11.3% (28/248) c 4.1% (3/74)c 52.0% (52/100) c 9.5% (7/74) c
Ovarian cancer 9 16.7% (22/132) 2.0% (3/147) 61.4% (81/132) 15.0% (22/147) Wang X et al. (2019)
Open in a new tab
a

Unknown.

b

Test cohort.

c

Validation cohort.

The clinical value of the autoantibody responses to CIP2A/p90 and other TAAs might be further validated by more studies of different cancers. The more precise circumscriptions about whether the expression level of anti-TAA autoantibodies varies with disease progression or the response to treatment, and when autoantibodies against these TAAs appear as early predictors of cancers, also needs further investigation (Liu J et al., 2011).

6 CIP2A/p90 as a potential therapeutic target in cancers

The overexpression of CIP2A/p90 can upregulate the drug resistance of tumor cells to chemotherapy (Liu et al., 2022). Based on the pathophysiology of cancer cells, it can be suggested that effective therapeutic responses against them require simultaneous inhibition of kinase signaling pathways and the reactivation of their inhibitors, such as PP2A (Soofiyani et al., 2017; Westermarck, 2018). CIP2A/p90 siRNA and some small-molecule compounds can inhibit some tumor cell proliferation and corresponding nude mice xenografts. The inhibition was related to the downregulation of CIP2A/p90, the downstream molecules of which could increase PP2A activity and attenuate AKT phosphorylation (Table 4).

TABLE 4.

Antitumor research related to CIP2A downregulation.

Compounds Suppressed tumor cells Inhibition of nude mice xenografts Reduce resistance References
CIP2A siRNA Human tongue squamous cell carcinoma (SCC) cell line CAL 27 Xenograft model of oral cancer cell CAL27 — a Cantini et al. (2013)
Bladder cancer cell (T24) Xenograft model of bladder cancer cell T24 — Xue et al. (2013)
Lapatinib Breast cancer cell (HCC 1937; MDA-MB-468/MDA-MB-231) — — Liu J et al. (2016)
Genistein Breast cancer cell (MCF-7-C3 and T47D) — — Zhao et al. (2016)
Fingolimod Breast cancer cell (MDA-MB-231and BT-474) Xenograft model of breast cancer cell MDA-MB-231 — Zhao et al. (2016)
Tamoxifen Breast cancer cell (MDA-MB-231, MDA-MB-468, MDA-MB-453, and SK-BR-3) Xenograft model of breast cancer cell MDA-MB-468 — Liu N et al. (2014)
Cucurbitacin B Breast cancer cell (MCF-7/Adr) — Doxorubicin Cai et al. (2016)
Glioblastoma multiform (GBM) cell, (DBTRG-05MG, U251MG, U118MG, U87MG, and LN229) Xenograft model of GBM cell U118MG — Qin et al. (2018)
Gastric cancer cell (SGC7901/DDP and SGC7901) — Cisplatin Liu et al. (2017d)
The t (8:21)-bearing AML cell line kasumi-1, acute promyelocytic leukemia (HL60), acute myelomonocytic leukemia (U937), chronic myelogenous leukemia (K562), and Burkitt’s lymphoma (Raji) and T-cell acute lymphoblastic leukemia (Molt-4) Xenotransplantation model of AML cell — Ma et al. (2019)
Human gefitinib-resistant NSCLC cell A549, NCI-H1299 (H1299), NCI-H1975 (H1975), NCI-H820 (H820), and human normal lung epithelial cell (16-HBE) H1975 cell transplantation model Gefitinib Liu et al. (2019)
Bortezomib HNSCC cell (Ca9-22, SAS and SCC-25) — — Lin et al. (2012)
Breast cancer cell (HCC-1937, MDA-MB-231 and MDA-MB-468) Xenograft model of breast cancer cell HCC-1937 — Tseng et al. (2012)
Colon cancer cell (LoVo) Xenograft model of colon cancer cell LoVo — Ding et al. (2014)
HCC cell (Sk-Hep1 and Huh-7) — Radiation Huang L.P et al. (2012)
Cervical cancer cell (SiHa) (Bortezomib and radiation combination) xenograft model of cervical cancer cell SiHa Radiation Huang P et al. (2012)
Leukemia cell (HL-60 and KG-1) Xenograft model of leukemia cell HL-60 — Liu et al. (2013)
Non-small cell lung cancer cell (HCC4006) — Erlotinib Saafan et al. (2021)
Bortezomib and its derivative HCC cell (Huh-7, Hep3B and Sk-Hep1) Xenograft model of HCC cell Huh-7 Anti-death receptor 5 antibodies CS-1008 Chen et al. (2010); Hou et al. (2013)
Carfilzomib Leukemia cell (HL-60, KG-1, THP-1 and K562) Xenograft model of Leukemia cell HL-60 and K562 — Liu et al. (2017a)
Ellagic acid Lung adenocarcinoma cell HOP62 and H1975 (harboring L858R/T790M EGFR mutation) Xenograft model of lung cancer cell HOP62 — Duan et al. (2019)
Polyphyllin I NSCLC cell A549 and DDP-resistant A549/DDP cells — Cisplatin Feng et al. (2019b)
GC cell (SGC7901, SGC7901/DDP and GES-1) Xenograft model of GC cell SGC7901/DDP Cisplatin Zhang et al. (2018)
PC cancer cell (PC3 and DU145) Xenograft model of PC cell DU145 — Liu C.Y et al. (2018)
Erlotinib NSCLC cell (H358) Xenograft model of NSCLC cell H358 — Wang C Y et al. (2014)
HCC (PLC5 and Hep3B) — — Yu H.C et al. (2013)
Erlotinib and its derivative HCC (Sk-Hep1) — — Chen et al. (2012)
Erlotinib derivative TD-19 NSCLC cell (H460) Xenograft model of NSCLC cell H460 — Chao et al. (2014)
Erlotinib derivative TD52 HCC (PLC5, Huh-7, Hep3B, and Sk-Hep1) Xenograft model of HCC cell PLC5 — Yu et al. (2014)
Triple-negative breast cancer (TNBC) cells (HCC-1937) Xenograft model of TNBC cell MDA-MB-468 — Liu et al. (2017b)
MDA-MB-231 and MDA-MB-468)
Afatinib NSCLC cell (H358 and H441) Xenograft model of NSCLC cell H358 — Chao et al. (2015)
Celastrol NSCLC cell (H1975 and A549) Xenograft model of NSCLC cell H1975 and A549 — Liu et al. (2014b)
Chondrosarcomas (CS) cell (SW1353 and JJ012) — — Wu et al. (2017)
Ethoxysan-guinarine NSCLC cell (H1975 and A549) — Cisplatin Liu et al. (2014a)
CRC cell (SW620, SW480, HT29 and HCT116) Xenograft model of CRC cells SW620 — Jin et al. (2018)
Temsirolimus Colon cancer cell (HCT-15 and SW480) Temsirolimus and cetuximab combination xenograft model of colon cancer cell HCT-15 Cetuximab Wang H.W et al. (2014)
Euxanthone CRC cell (HT29, HCT116, SW620, LOVO and SW480) Xenograft model of CRC cells HT29 — Wang et al. (2018)
Gambogenic acid HCC (Hep G2 and Bel-7402) — — Yu et al. (2016)
Huaier polysaccharide (HP-1) ccRCC cells (A498 and 786-O) Xenograft model of ccRCC cells A498 Sunitinib Fang et al. (2019)
FTY720 Neuroblastoma cell SK-N-AS (CRL-2137), SK-N-BE (2) (CRL-2271), SH-EP and WAC (2) Xenograft model of neuroblastoma cells SH-EP and WAC (2) — Williams et al. (2019)
Medulloblastoma cell (D341, D384, and D425) Xenograft model of medulloblastoma cells D341, D384, and D425 — Garner et al. (2018)
2,5-Dimethyl Celecoxib Glioblastoma cell (LN229, A172, U251 and U87MG) Xenotransplantation model of glioblastoma cell LN229 cells in nude mice — Gao et al. (2021)
Polyphyllins I and VII NSCLC cell (A549 and A549/DDP) — Cisplatin Feng et al. (2019b)
(+)-Cyanidan-3-ol Squamous cell skin cancer (SCSC) cell (A431) DMBA/TPA-induced SCSC and xenograft model of SCSC cell A431 — Monga et al. (2022)
A431
Open in a new tab
a

Unknown.

According to Table 4, the mechanism by which some small-molecule compounds downregulate CIP2A/p90 has been elucidated. Hypoglycemia and metformin impair the metabolic plasticity and growth of tumors by regulating the PP2A-GSK3b-MCL-1 axis (Elgendy et al., 2019). Lapatinib, erlotinib derivative TD52, and afatinib interfered transcription factor Elk1 combined with the CIP2A/p90 promoter further downregulate the expression of CIP2A/p90 separately in breast cancer cells, liver cancer cells, and NSCLC cells (Yu et al., 2014; Chao et al., 2015; Liu C Y et al., 2016; Liu et al., 2017a). Bortezomib, as a proteasome inhibitor, has an anti-tumor effect in HCC, HNSCC, leukemia, breast cancer, and colon cancer by inhibiting the CIP2A-PP2A-AKT signaling pathway (Chen et al., 2010; Lin et al., 2012; Tseng et al., 2012; Liu et al., 2013; Ding et al., 2014). Celastrol, bound to CIP2A/p90 in NSCLC cells, promotes the connection of CIP2A/p90 with the carboxyl terminus of Hsp70-interacting protein (CHIP) and induces the degradation of CIP2A/p90 (Liu et al., 2014b). Gambogenic acid induces the degradation of CIP2A/p90 through the ubiquitin–proteasome pathway in HCC cells (Yu et al., 2016). Notably, the direct and accurate antagonists of CIP2A/p90 are still unknown. There are multiple challenges in establishing direct CIP2A/p90-target drugs as effective clinical anticancer therapies.

7 Conclusion

CIP2A/p90 is overexpressed in most types of cancer and is positively correlated with the poor prognosis of many patients. The interaction among CIP2A/p90, PP2A, and c-Myc is an important mechanism of CIP2A/p90 in promoting cancer. Owing to the nature of CIP2A/p90, which can play important roles in the proliferation, apoptosis, invasion, migration, EMT, cell cycle, and drug resistance of tumor cells, it can be used as a potential diagnostic biomarker, as well as an antitumor drug target. However, there are still some important issues to be resolved: (1) the function of CIP2A/p90 in both cell proliferation and drug resistance suggests that it plays an important role in cancer stem cells, which have drug resistance and rapid proliferation. (2) The signaling pathways and regulation networks of CIP2A/p90 are complex. Genomic or systems-level analysis with new tools and technologies will reveal how the signaling pathways and regulators of CIP2A/p90 contribute to tumorigenesis. (3) The precise molecular structure of CIP2A/p90 has not yet been resolved. Therefore, the direct antagonists of CIP2A/p90 still need further investigation and additional application in clinical therapy. (4) The clinical value of autoantibody against CIP2A/p90 as biomarker in cancer needs to be further clinically validated. Overall, there is an urgent need for large studies that will clearly validate the clinical significance of CIP2A/p90, the potential benefit of which is huge.

Funding Statement

This work was supported by the Medical Science and Technique Foundation of Henan Province (LHGJ20210172), the Science and Technique Foundation of Henan Province (222102310424), and the Project of international scientific and technological cooperation in Henan Province (182102410023).

Author contributions

XC conceived the study. BC and HH conducted the study and drafted the application sections. BC contributed to the writing and review of the manuscript. All authors read, revised, and approved the final manuscript.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

  1. Adam S., Rossi S. E., Moatti N., De Marco Zompit M., Xue Y., Ng T. F., et al. (2021). The CIP2A-TOPBP1 axis safeguards chromosome stability and is a synthetic lethal target for BRCA-mutated cancer. Nat. Cancer 2, 1357–1371. 10.1038/s43018-021-00266-w [DOI] [PubMed] [Google Scholar]
  2. Alzahrani R., Alrehaili A. A., Gharib A. F., Anjum F., Ismail K. A., Elsawy W. H. (2020). Cancerous inhibitor of protein phosphatase 2A as a molecular marker for aggressiveness and survival in oral squamous cell carcinoma. J. Cancer Prev. 25, 21–26. 10.15430/jcp.2020.25.1.21 [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Balliu M., Cellai C., Lulli M., Laurenzana A., Torre E., Vannucchi A. M., et al. (2016). HDAC1 controls CIP2A transcription in human colorectal cancer cells. Oncotarget 7, 25862–25871. 10.18632/oncotarget.8406 [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Barragán E., Chillón M. C., Castelló-Cros R., Marcotegui N., Prieto M. I., Hoyos M., et al. (2015). CIP2A high expression is a poor prognostic factor in normal karyotype acute myeloid leukemia. Haematologica 100, e183–e185. 10.3324/haematol.2014.118117 [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Baskaran R., Velmurugan B. K. (2018). Protein phosphatase 2A as therapeutic targets in various disease models. Life Sci. 210, 40–46. 10.1016/j.lfs.2018.08.063 [DOI] [PubMed] [Google Scholar]
  6. Birkman E. M., Elzagheid A., Jokilehto T., Avoranta T., Korkeila E., Kulmala J., et al. (2018). Protein phosphatase 2A (PP2A) inhibitor CIP2A indicates resistance to radiotherapy in rectal cancer. Cancer Med. 7, 698–706. 10.1002/cam4.1361 [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Böckelman C., Hagström J., Mäkinen L. K., Keski-Säntti H., Häyry V., Lundin J., et al. (2011a). High CIP2A immunoreactivity is an independent prognostic indicator in early-stage tongue cancer. Br. J. Cancer 104, 1890–1895. 10.1038/bjc.2011.167 [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Böckelman C., Koskensalo S., Hagström J., Lundin M., Ristimäki A., Haglund C. (2012). CIP2A overexpression is associated with c-Myc expression in colorectal cancer. Cancer Biol. Ther. 13, 289–295. 10.4161/cbt.18922 [DOI] [PubMed] [Google Scholar]
  9. Böckelman C., Lassus H., Hemmes A., Leminen A., Westermarck J., Haglund C., et al. (2011b). Prognostic role of CIP2A expression in serous ovarian cancer. Br. J. Cancer 105, 989–995. 10.1038/bjc.2011.346 [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Cai F., Zhang L., Xiao X., Duan C., Huang Q., Fan C., et al. (2016). Cucurbitacin B reverses multidrug resistance by targeting CIP2A to reactivate protein phosphatase 2A in MCF-7/adriamycin cells. Oncol. Rep. 36, 1180–1186. 10.3892/or.2016.4892 [DOI] [PubMed] [Google Scholar]
  11. Cantini L., Attaway C. C., Butler B., Andino L. M., Sokolosky M. L., Jakymiw A. (2013). Fusogenic-oligoarginine peptide-mediated delivery of siRNAs targeting the CIP2A oncogene into oral cancer cells. PLoS One 8, e73348. 10.1371/journal.pone.0073348 [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Celikden S. G., Baspinar S., Ozturk S. A., Karaibrahimoglu A. (2020). CIP2A expression in high grade prostatic intraepithelial neoplasia and prostate adenocarcinoma: A tissue mıcroarray study. Malays J. Pathol. 42, 227–236. [PubMed] [Google Scholar]
  13. Cha G., Xu J., Xu X., Li B., Lu S., Nanding A., et al. (2017). High expression of CIP2A protein is associated with tumor aggressiveness in stage I-III NSCLC and correlates with poor prognosis. Onco Targets Ther. 10, 5907–5914. 10.2147/ott.S148250 [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Chao T. T., Maa H. C., Wang C. Y., Pei D., Liang Y. J., Yang Y. F., et al. (2016). CIP2A is a poor prognostic factor and can be a diagnostic marker in papillary thyroid carcinoma. Apmis 124, 1031–1037. 10.1111/apm.12602 [DOI] [PubMed] [Google Scholar]
  15. Chao T. T., Wang C. Y., Chen Y. L., Lai C. C., Chang F. Y., Tsai Y. T., et al. (2015). Afatinib induces apoptosis in NSCLC without EGFR mutation through Elk-1-mediated suppression of CIP2A. Oncotarget 6, 2164–2179. 10.18632/oncotarget.2941 [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Chao T. T., Wang C. Y., Lai C. C., Chen Y. L., Tsai Y. T., Chen P. T., et al. (2014). TD-19, an erlotinib derivative, induces epidermal growth factor receptor wild-type nonsmall-cell lung cancer apoptosis through CIP2A-mediated pathway. J. Pharmacol. Exp. Ther. 351, 352–358. 10.1124/jpet.114.215418 [DOI] [PubMed] [Google Scholar]
  17. Chen J. S., Wu B. B., Bao H. L., Du J. M., Zhang S. C., Zheng Y. H. (2015). Relationship between CIP2A expression, and prognosis and MDR-related proteins in patients with advanced gastric cancer. Int. J. Clin. Exp. Pathol. 8, 15007–15012. [PMC free article] [PubMed] [Google Scholar]
  18. Chen K. F., Liu C. Y., Lin Y. C., Yu H. C., Liu T. H., Hou D. R., et al. (2010). CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells. Oncogene 29, 6257–6266. 10.1038/onc.2010.357 [DOI] [PubMed] [Google Scholar]
  19. Chen K. F., Pao K. C., Su J. C., Chou Y. C., Liu C. Y., Chen H. J., et al. (2012). Development of erlotinib derivatives as CIP2A-ablating agents independent of EGFR activity. Bioorg Med. Chem. 20, 6144–6153. 10.1016/j.bmc.2012.08.039 [DOI] [PubMed] [Google Scholar]
  20. Chen K. F., Yen C. C., Lin J. K., Chen W. S., Yang S. H., Jiang J. K., et al. (2015). Cancerous inhibitor of protein phosphatase 2A (CIP2A) is an independent prognostic marker in wild-type KRAS metastatic colorectal cancer after colorectal liver metastasectomy. BMC Cancer 15, 301. 10.1186/s12885-015-1300-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Chen N., Li X., Chintala N. K., Tano Z. E., Adusumilli P. S. (2018). Driving CARs on the uneven road of antigen heterogeneity in solid tumors. Curr. Opin. Immunol. 51, 103–110. 10.1016/j.coi.2018.03.002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Chen W., Liang J. L., Zhou K., Zeng Q. L., Ye J. W., Huang M. J. (2020). Effect of CIP2A and its mechanism of action in the malignant biological behavior of colorectal cancer. Cell Commun. Signal 18, 67. 10.1186/s12964-020-00545-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Chen W., Wang Z., Jiang C., Ding Y. (2013). PP2A-Mediated anticancer therapy. Gastroenterol. Res. Pract. 2013, 675429. 10.1155/2013/675429 [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Choi Y. A., Koo J. S., Park J. S., Park M. Y., Jeong A. L., Oh K. S., et al. (2014). Estradiol enhances CIP2A expression by the activation of p70 S6 kinase. Endocr. Relat. Cancer 21, 189–202. 10.1530/erc-13-0453 [DOI] [PubMed] [Google Scholar]
  25. Clark R. E., Basabrain A. A., Austin G. M., Holcroft A. K., Loaiza S., Apperley J. F., et al. (2021). Validation of CIP2A as a biomarker of subsequent disease progression and treatment failure in chronic myeloid leukaemia. Cancers (Basel) 13, 2155. 10.3390/cancers13092155 [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Côme C., Laine A., Chanrion M., Edgren H., Mattila E., Liu X., et al. (2009). CIP2A is associated with human breast cancer aggressivity. Clin. Cancer Res. 15, 5092–5100. 10.1158/1078-0432.Ccr-08-3283 [DOI] [PubMed] [Google Scholar]
  27. Dang C. V. (2012). MYC on the path to cancer. Cell 149, 22–35. 10.1016/j.cell.2012.03.003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. De P., Carlson J., Leyland-Jones B., Dey N. (2014). Oncogenic nexus of cancerous inhibitor of protein phosphatase 2A (CIP2A): An oncoprotein with many hands. Oncotarget 5, 4581–4602. 10.18632/oncotarget.2127 [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Denk S., Schmidt S., Schurr Y., Schwarz G., Schote F., Diefenbacher M., et al. (2021). CIP2A regulates MYC translation (via its 5'UTR) in colorectal cancer. Int. J. Colorectal Dis. 36, 911–918. 10.1007/s00384-020-03772-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Dhanasekaran R., Deutzmann A., Mahauad-Fernandez W. D., Hansen A. S., Gouw A. M., Felsher D. W. (2022). The MYC oncogene - the grand orchestrator of cancer growth and immune evasion. Nat. Rev. Clin. Oncol. 19, 23–36. 10.1038/s41571-021-00549-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Ding Y., Wang Y., Ju S., Wu X., Zhu W., Shi F., et al. (2014). Role of CIP2A in the antitumor effect of bortezomib in colon cancer. Mol. Med. Rep. 10, 387–392. 10.3892/mmr.2014.2173 [DOI] [PubMed] [Google Scholar]
  32. Dong Q. Z., Wang Y., Dong X. J., Li Z. X., Tang Z. P., Cui Q. Z., et al. (2011). CIP2A is overexpressed in non-small cell lung cancer and correlates with poor prognosis. Ann. Surg. Oncol. 18, 857–865. 10.1245/s10434-010-1313-8 [DOI] [PubMed] [Google Scholar]
  33. Duan J., Zhan J. C., Wang G. Z., Zhao X. C., Huang W. D., Zhou G. B. (2019). The red wine component ellagic acid induces autophagy and exhibits anti-lung cancer activity in vitro and in vivo . J. Cell Mol. Med. 23, 143–154. 10.1111/jcmm.13899 [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Duffy M. J., O'Grady S., Tang M., Crown J. (2021). MYC as a target for cancer treatment. Cancer Treat. Rev. 94, 102154. 10.1016/j.ctrv.2021.102154 [DOI] [PubMed] [Google Scholar]
  35. Elgendy M., Cirò M., Hosseini A., Weiszmann J., Mazzarella L., Ferrari E., et al. (2019). Combination of hypoglycemia and metformin impairs tumor metabolic plasticity and growth by modulating the PP2A-gsk3β-MCL-1 Axis. Cancer Cell 35, 798–815.e5. 10.1016/j.ccell.2019.03.007 [DOI] [PubMed] [Google Scholar]
  36. Fang L., Zhang Y., Zang Y., Chai R., Zhong G., Li Z., et al. (2019). HP-1 inhibits the progression of ccRCC and enhances sunitinib therapeutic effects by suppressing EMT. Carbohydr. Polym. 223, 115109. 10.1016/j.carbpol.2019.115109 [DOI] [PubMed] [Google Scholar]
  37. Fang Y., Li Z., Wang X., Zhang S. (2012). CIP2A is overexpressed in human ovarian cancer and regulates cell proliferation and apoptosis. Tumour Biol. 33, 2299–2306. 10.1007/s13277-012-0492-2 [DOI] [PubMed] [Google Scholar]
  38. Farrington C. C., Yuan E., Mazhar S., Izadmehr S., Hurst L., Allen-Petersen B. L., et al. (2020). Protein phosphatase 2A activation as a therapeutic strategy for managing MYC-driven cancers. J. Biol. Chem. 295, 757–770. 10.1074/jbc.RA119.011443 [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Feng F., Cheng P., Wang C., Wang Y., Wang W. (2019a). Polyphyllin I and VII potentiate the chemosensitivity of A549/DDP cells to cisplatin by enhancing apoptosis, reversing EMT and suppressing the CIP2A/AKT/mTOR signaling axis. Oncol. Lett. 18, 5428–5436. 10.3892/ol.2019.10895 [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Feng F. F., Cheng P., Sun C., Wang H., Wang W. (2019b). Inhibitory effects of polyphyllins I and VII on human cisplatin-resistant NSCLC via p53 upregulation and CIP2A/AKT/mTOR signaling axis inhibition. Chin. J. Nat. Med. 17, 768–777. 10.1016/s1875-5364(19)30093-7 [DOI] [PubMed] [Google Scholar]
  41. Flørenes V. A., Emilsen E., Dong H. P., Førsund M., Holm R., Slipicevic A. (2015). Cellular localization of CIP2A determines its prognostic impact in superficial spreading and nodular melanoma. Cancer Med. 4, 903–913. 10.1002/cam4.425 [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Gao D., Nyalali A. M. K., Hou Y., Xu Y., Zhou J., Zhao W., et al. (2021). 2,5-Dimethyl celecoxib inhibits proliferation and cell cycle and induces apoptosis in glioblastoma by suppressing CIP2A/PP2A/akt signaling Axis. J. Mol. Neurosci. 71, 1703–1713. 10.1007/s12031-020-01773-8 [DOI] [PubMed] [Google Scholar]
  43. Gao F., Xu T., Wang X., Zhong S., Chen S., Zhang M., et al. (2017). CIP2A mediates fibronectin-induced bladder cancer cell proliferation by stabilizing β-catenin. J. Exp. Clin. Cancer Res. 36, 70. 10.1186/s13046-017-0539-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Gao H., Li Y., Lin T., Cheng Y., Ma Y. (2020). Downregulation of CIP2A inhibits cancer cell proliferation and vascularization in renal clear cell carcinoma. Biomed. Pap. Med. Fac. Univ. Palacky. Olomouc Czech Repub. 164, 196–202. 10.5507/bp.2019.031 [DOI] [PubMed] [Google Scholar]
  45. Garner E. F., Williams A. P., Stafman L. L., Aye J. M., Mroczek-Musulman E., Moore B. P., et al. (2018). FTY720 decreases tumorigenesis in group 3 medulloblastoma patient-derived xenografts. Sci. Rep. 8, 6913. 10.1038/s41598-018-25263-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Grieb B. C., Eischen C. M. (2022). MTBP and myc: A dynamic duo in proliferation, cancer, and aging. Biol. (Basel) 11, 881. 10.3390/biology11060881 [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. He H., Wu G., Li W., Cao Y., Liu Y. (2012). CIP2A is highly expressed in hepatocellular carcinoma and predicts poor prognosis. Diagn Mol. Pathol. 21, 143–149. 10.1097/PDM.0b013e318249fd8b [DOI] [PubMed] [Google Scholar]
  48. Hoshino I., Nagata M., Takiguchi N., Nabeya Y., Ikeda A., Yokoi S., et al. (2017). Panel of autoantibodies against multiple tumor-associated antigens for detecting gastric cancer. Cancer Sci. 108, 308–315. 10.1111/cas.13158 [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Hou D. R., Huang A. C., Shiau C. W., Wang C. Y., Yu H. C., Chen K. F. (2013). Bortezomib congeners induce apoptosis of hepatocellular carcinoma via CIP2A inhibition. Molecules 18, 15398–15411. 10.3390/molecules181215398 [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Huang C. Y., Wei C. C., Chen K. C., Chen H. J., Cheng A. L., Chen K. F. (2012). Bortezomib enhances radiation-induced apoptosis in solid tumors by inhibiting CIP2A. Cancer Lett. 317, 9–15. 10.1016/j.canlet.2011.11.005 [DOI] [PubMed] [Google Scholar]
  51. Huang J., Jia J., Tong Q., Liu J., Qiu J., Sun R., et al. (2015). Knockdown of cancerous inhibitor of protein phosphatase 2A may sensitize metastatic castration-resistant prostate cancer cells to cabazitaxel chemotherapy. Tumour Biol. 36, 1589–1594. 10.1007/s13277-014-2748-5 [DOI] [PubMed] [Google Scholar]
  52. Huang L. P., Savoly D., Sidi A. A., Adelson M. E., Mordechai E., Trama J. P. (2012). CIP2A protein expression in high-grade, high-stage bladder cancer. Cancer Med. 1, 76–81. 10.1002/cam4.15 [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Huang P., Qiu J., You J., Hong J., Li B., Zhou K., et al. (2012). Expression and prognostic significance of CIP2A mRNA in hepatocellular carcinoma and nontumoral liver tissues. Biomarkers 17, 422–429. 10.3109/1354750x.2012.680608 [DOI] [PubMed] [Google Scholar]
  54. Huang P., Yan R., Zhang X., Wang L., Ke X., Qu Y. (2019). Activating Wnt/β-catenin signaling pathway for disease therapy: Challenges and opportunities. Pharmacol. Ther. 196, 79–90. 10.1016/j.pharmthera.2018.11.008 [DOI] [PubMed] [Google Scholar]
  55. Jeong A. L., Lee S., Park J. S., Han S., Jang C. Y., Lim J. S., et al. (2014). Cancerous inhibitor of protein phosphatase 2A (CIP2A) protein is involved in centrosome separation through the regulation of NIMA (never in mitosis gene A)-related kinase 2 (NEK2) protein activity. J. Biol. Chem. 289, 28–40. 10.1074/jbc.M113.507954 [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Jhunjhunwala S., Hammer C., Delamarre L. (2021). Antigen presentation in cancer: Insights into tumour immunogenicity and immune evasion. Nat. Rev. Cancer 21, 298–312. 10.1038/s41568-021-00339-z [DOI] [PubMed] [Google Scholar]
  57. Ji J., Zhen W., Si Y., Ma W., Zheng L., Li C., et al. (2018). Increase in CIP2A expression is associated with cisplatin chemoresistance in gastric cancer. Cancer Biomark. 21, 307–316. 10.3233/cbm-170416 [DOI] [PubMed] [Google Scholar]
  58. Jin L., Si Y., Hong X., Liu P., Zhu B., Yu H., et al. (2018). Ethoxysanguinarine inhibits viability and induces apoptosis of colorectal cancer cells by inhibiting CIP2A. Int. J. Oncol. 52, 1569–1578. 10.3892/ijo.2018.4323 [DOI] [PubMed] [Google Scholar]
  59. Jung H. M., Patel R. S., Phillips B. L., Wang H., Cohen D. M., Reinhold W. C., et al. (2013). Tumor suppressor miR-375 regulates MYC expression via repression of CIP2A coding sequence through multiple miRNA-mRNA interactions. Mol. Biol. Cell 24, 1638–1648. 10.1091/mbc.E12-12-0891 [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Jung H. M., Phillips B. L., Chan E. K. (2014). miR-375 activates p21 and suppresses telomerase activity by coordinately regulating HPV E6/E7, E6AP, CIP2A, and 14-3-3ζ. Mol. Cancer 13, 80. 10.1186/1476-4598-13-80 [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Junttila M. R., Puustinen P., Niemelä M., Ahola R., Arnold H., Böttzauw T., et al. (2007). CIP2A inhibits PP2A in human malignancies. Cell 130, 51–62. 10.1016/j.cell.2007.04.044 [DOI] [PubMed] [Google Scholar]
  62. Kauko O., Westermarck J. (2018). Non-genomic mechanisms of protein phosphatase 2A (PP2A) regulation in cancer. Int. J. Biochem. Cell Biol. 96, 157–164. 10.1016/j.biocel.2018.01.005 [DOI] [PubMed] [Google Scholar]
  63. Khan M. M., Kalim U. U., Khan M. H., Lahesmaa R. (2021). PP2A and its inhibitors in helper T-cell differentiation and autoimmunity. Front. Immunol. 12, 786857. 10.3389/fimmu.2021.786857 [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Khan M. M., Ullah U., Khan M. H., Kong L., Moulder R., Välikangas T., et al. (2020a). CIP2A constrains Th17 differentiation by modulating STAT3 signaling. iScience 23, 100947. 10.1016/j.isci.2020.100947 [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Khan M. M., Välikangas T., Khan M. H., Moulder R., Ullah U., Bhosale S. D., et al. (2020b). Protein interactome of the Cancerous Inhibitor of protein phosphatase 2A (CIP2A) in Th17 cells. Curr. Res. Immunol. 1, 10–22. 10.1016/j.crimmu.2020.02.001 [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Khan R., Kulasiri D., Samarasinghe S. (2021). Functional repertoire of protein kinases and phosphatases in synaptic plasticity and associated neurological disorders. Neural Regen. Res. 16, 1150–1157. 10.4103/1673-5374.300331 [DOI] [PMC free article] [PubMed] [Google Scholar]
  67. Khanna A., Böckelman C., Hemmes A., Junttila M. R., Wiksten J. P., Lundin M., et al. (2009). MYC-dependent regulation and prognostic role of CIP2A in gastric cancer. J. Natl. Cancer Inst. 101, 793–805. 10.1093/jnci/djp103 [DOI] [PubMed] [Google Scholar]
  68. Khanna A., Kauko O., Böckelman C., Laine A., Schreck I., Partanen J. I., et al. (2013). Chk1 targeting reactivates PP2A tumor suppressor activity in cancer cells. Cancer Res. 73, 6757–6769. 10.1158/0008-5472.Can-13-1002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  69. Khanna A., Okkeri J., Bilgen T., Tiirikka T., Vihinen M., Visakorpi T., et al. (2011). ETS1 mediates MEK1/2-dependent overexpression of cancerous inhibitor of protein phosphatase 2A (CIP2A) in human cancer cells. PLoS One 6, e17979. 10.1371/journal.pone.0017979 [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. Khanna A., Rane J. K., Kivinummi K. K., Urbanucci A., Helenius M. A., Tolonen T. T., et al. (2015). CIP2A is a candidate therapeutic target in clinically challenging prostate cancer cell populations. Oncotarget 6, 19661–19670. 10.18632/oncotarget.3875 [DOI] [PMC free article] [PubMed] [Google Scholar]
  71. Khanna A., Thoms J. A. I., Stringer B. W., Chung S. A., Ensbey K. S., Jue T. R., et al. (2020). Constitutive CHK1 expression drives a pSTAT3-cip2a circuit that promotes glioblastoma cell survival and growth. Mol. Cancer Res. 18, 709–722. 10.1158/1541-7786.Mcr-19-0934 [DOI] [PubMed] [Google Scholar]
  72. Kim J. S., Kim E. J., Oh J. S., Park I. C., Hwang S. G. (2013). CIP2A modulates cell-cycle progression in human cancer cells by regulating the stability and activity of Plk1. Cancer Res. 73, 6667–6678. 10.1158/0008-5472.Can-13-0888 [DOI] [PubMed] [Google Scholar]
  73. Kleszcz R., Szymańska A., Krajka-Kuźniak V., Baer-Dubowska W., Paluszczak J. (2019). Inhibition of CBP/β-catenin and porcupine attenuates Wnt signaling and induces apoptosis in head and neck carcinoma cells. Cell Oncol. (Dordr) 42, 505–520. 10.1007/s13402-019-00440-4 [DOI] [PubMed] [Google Scholar]
  74. Laine A., Nagelli S. G., Farrington C., Butt U., Cvrljevic A. N., Vainonen J. P., et al. (2021). CIP2A interacts with TopBP1 and drives basal-like breast cancer tumorigenesis. Cancer Res. 81, 4319–4331. 10.1158/0008-5472.Can-20-3651 [DOI] [PMC free article] [PubMed] [Google Scholar]
  75. Laine A., Sihto H., Come C., Rosenfeldt M. T., Zwolinska A., Niemelä M., et al. (2013). Senescence sensitivity of breast cancer cells is defined by positive feedback loop between CIP2A and E2F1. Cancer Discov. 3, 182–197. 10.1158/2159-8290.Cd-12-0292 [DOI] [PMC free article] [PubMed] [Google Scholar]
  76. Lei N., Peng B., Zhang J. Y. (2014). CIP2A regulates cell proliferation via the AKT signaling pathway in human lung cancer. Oncol. Rep. 32, 1689–1694. 10.3892/or.2014.3375 [DOI] [PMC free article] [PubMed] [Google Scholar]
  77. Li J., Karki A., Hodges K. B., Ahmad N., Zoubeidi A., Strebhardt K., et al. (2015). Cotargeting polo-like kinase 1 and the wnt/β-catenin signaling pathway in castration-resistant prostate cancer. Mol. Cell Biol. 35, 4185–4198. 10.1128/mcb.00825-15 [DOI] [PMC free article] [PubMed] [Google Scholar]
  78. Li J., Qin B., Huang M., Ma Y., Li D., Li W., et al. (2021). Tumor-associated antigens (TAAs) for the serological diagnosis of osteosarcoma. Front. Immunol. 12, 665106. 10.3389/fimmu.2021.665106 [DOI] [PMC free article] [PubMed] [Google Scholar]
  79. Li Y. R., Zong R. Q., Zhang H. Y., Meng X. Y., Wu F. X. (2022). Mechanism analysis of LINC00665 and its peptides CIP2A-BP in hepatocellular carcinoma. Front. Genet. 13, 861096. 10.3389/fgene.2022.861096 [DOI] [PMC free article] [PubMed] [Google Scholar]
  80. Li Y., Wang M., Zhu X., Cao X., Wu Y., Fang F. (2019). Prognostic significance of CIP2A in esophagogastric junction adenocarcinoma: A study of 65 patients and a meta-analysis. Dis. Markers 2019, 2312439. 10.1155/2019/2312439 [DOI] [PMC free article] [PubMed] [Google Scholar]
  81. Lin L., Wang Y. (2018). miR-548b-3p regulates proliferation, apoptosis, and mitochondrial function by targeting CIP2A in hepatocellular carcinoma. Biomed. Res. Int. 2018, 7385426. 10.1155/2018/7385426 [DOI] [PMC free article] [PubMed] [Google Scholar]
  82. Lin Y. C., Chen K. C., Chen C. C., Cheng A. L., Chen K. F. (2012). CIP2A-mediated Akt activation plays a role in bortezomib-induced apoptosis in head and neck squamous cell carcinoma cells. Oral Oncol. 48, 585–593. 10.1016/j.oraloncology.2012.01.012 [DOI] [PubMed] [Google Scholar]
  83. Liu C. Y., Hsieh F. S., Chu P. Y., Tsai W. C., Huang C. T., Yu Y. B., et al. (2017a). Carfilzomib induces leukaemia cell apoptosis via inhibiting ELK1/KIAA1524 (Elk-1/CIP2A) and activating PP2A not related to proteasome inhibition. Br. J. Haematol. 177, 726–740. 10.1111/bjh.14620 [DOI] [PubMed] [Google Scholar]
  84. Liu C. Y., Hsu C. C., Huang T. T., Lee C. H., Chen J. L., Yang S. H., et al. (2018). ER stress-related ATF6 upregulates CIP2A and contributes to poor prognosis of colon cancer. Mol. Oncol. 12, 1706–1717. 10.1002/1878-0261.12365 [DOI] [PMC free article] [PubMed] [Google Scholar]
  85. Liu C. Y., Hu M. H., Hsu C. J., Huang C. T., Wang D. S., Tsai W. C., et al. (2016). Lapatinib inhibits CIP2A/PP2A/p-Akt signaling and induces apoptosis in triple negative breast cancer cells. Oncotarget 7, 9135–9149. 10.18632/oncotarget.7035 [DOI] [PMC free article] [PubMed] [Google Scholar]
  86. Liu C. Y., Huang T. T., Huang C. T., Hu M. H., Wang D. S., Wang W. L., et al. (2017b). EGFR-independent Elk1/CIP2A signalling mediates apoptotic effect of an erlotinib derivative TD52 in triple-negative breast cancer cells. Eur. J. Cancer 72, 112–123. 10.1016/j.ejca.2016.11.012 [DOI] [PubMed] [Google Scholar]
  87. Liu C. Y., Hung M. H., Wang D. S., Chu P. Y., Su J. C., Teng T. H., et al. (2014). Tamoxifen induces apoptosis through cancerous inhibitor of protein phosphatase 2A-dependent phospho-Akt inactivation in estrogen receptor-negative human breast cancer cells. Breast Cancer Res. 16, 431. 10.1186/s13058-014-0431-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  88. Liu C. Y., Shiau C. W., Kuo H. Y., Huang H. P., Chen M. H., Tzeng C. H., et al. (2013). Cancerous inhibitor of protein phosphatase 2A determines bortezomib-induced apoptosis in leukemia cells. Haematologica 98, 729–738. 10.3324/haematol.2011.050187 [DOI] [PMC free article] [PubMed] [Google Scholar]
  89. Liu H., Qiu H., Song Y., Liu Y., Wang H., Lu M., et al. (2017). Cip2a promotes cell cycle progression in triple-negative breast cancer cells by regulating the expression and nuclear export of p27Kip1. Oncogene 36, 1952–1964. 10.1038/onc.2016.355 [DOI] [PubMed] [Google Scholar]
  90. Liu J., Wang M., Zhang X., Wang Q., Qi M., Hu J., et al. (2016). CIP2A is associated with multidrug resistance in cervical adenocarcinoma by a P-glycoprotein pathway. Tumour Biol. 37, 2673–2682. 10.1007/s13277-015-4032-8 [DOI] [PubMed] [Google Scholar]
  91. Liu J., Wang X., Zhou G., Wang H., Xiang L., Cheng Y., et al. (2011). Cancerous inhibitor of protein phosphatase 2A is overexpressed in cervical cancer and upregulated by human papillomavirus 16 E7 oncoprotein. Gynecol. Oncol. 122, 430–436. 10.1016/j.ygyno.2011.04.031 [DOI] [PubMed] [Google Scholar]
  92. Liu N., He Q. M., Chen J. W., Li Y. Q., Xu Y. F., Ren X. Y., et al. (2014). Overexpression of CIP2A is an independent prognostic indicator in nasopharyngeal carcinoma and its depletion suppresses cell proliferation and tumor growth. Mol. Cancer 13, 111. 10.1186/1476-4598-13-111 [DOI] [PMC free article] [PubMed] [Google Scholar]
  93. Liu P., Xiang Y., Liu X., Zhang T., Yang R., Chen S., et al. (2019). Cucurbitacin B induces the lysosomal degradation of EGFR and suppresses the CIP2A/PP2A/akt signaling Axis in gefitinib-resistant non-small cell lung cancer. Molecules 24, 647. 10.3390/molecules24030647 [DOI] [PMC free article] [PubMed] [Google Scholar]
  94. Liu S., Bu X., Kan A., Luo L., Xu Y., Chen H., et al. (2022). SP1-induced lncRNA DUBR promotes stemness and oxaliplatin resistance of hepatocellular carcinoma via E2F1-CIP2A feedback. Cancer Lett. 528, 16–30. 10.1016/j.canlet.2021.12.026 [DOI] [PubMed] [Google Scholar]
  95. Liu W., Peng B., Lu Y., Xu W., Qian W., Zhang J. Y. (2011). Autoantibodies to tumor-associated antigens as biomarkers in cancer immunodiagnosis. Autoimmun. Rev. 10, 331–335. 10.1016/j.autrev.2010.12.002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  96. Liu X X., Chai Y., Li J., Ren P., Liu M., Dai L., et al. (2014). Autoantibody response to a novel tumor-associated antigen p90/CIP2A in breast cancer immunodiagnosis. Tumour Biol. 35, 2661–2667. 10.1007/s13277-013-1350-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  97. Liu X., Cao W., Qin S., Zhang T., Zheng J., Dong Y., et al. (2017c). Overexpression of CIP2A is associated with poor prognosis in multiple myeloma. Signal Transduct. Target Ther. 2, 17013. 10.1038/sigtrans.2017.13 [DOI] [PMC free article] [PubMed] [Google Scholar]
  98. Liu X., Duan C., Ji J., Zhang T., Yuan X., Zhang Y., et al. (2017d). Cucurbitacin B induces autophagy and apoptosis by suppressing CIP2A/PP2A/mTORC1 signaling axis in human cisplatin resistant gastric cancer cells. Oncol. Rep. 38, 271–278. 10.3892/or.2017.5648 [DOI] [PubMed] [Google Scholar]
  99. Liu X., Sun Z., Deng J., Liu J., Ma K., Si Y., et al. (2018). Polyphyllin I inhibits invasion and epithelial-mesenchymal transition via CIP2A/PP2A/ERK signaling in prostate cancer. Int. J. Oncol. 53, 1279–1288. 10.3892/ijo.2018.4464 [DOI] [PubMed] [Google Scholar]
  100. Liu Z., Ma L., Wen Z. S., Cheng Y. X., Zhou G. B. (2014a). Ethoxysanguinarine induces inhibitory effects and downregulates CIP2A in lung cancer cells. ACS Med. Chem. Lett. 5, 113–118. 10.1021/ml400341k [DOI] [PMC free article] [PubMed] [Google Scholar]
  101. Liu Z., Ma L., Wen Z. S., Hu Z., Wu F. Q., Li W., et al. (2014b). Cancerous inhibitor of PP2A is targeted by natural compound celastrol for degradation in non-small-cell lung cancer. Carcinogenesis 35, 905–914. 10.1093/carcin/bgt395 [DOI] [PMC free article] [PubMed] [Google Scholar]
  102. Lu Y. F., Zhang L., Waye M. M., Fu W. M., Zhang J. F. (2015). MiR-218 mediates tumorigenesis and metastasis: Perspectives and implications. Exp. Cell Res. 334, 173–182. 10.1016/j.yexcr.2015.03.027 [DOI] [PubMed] [Google Scholar]
  103. Lucas C. M., Harris R. J., Holcroft A. K., Scott L. J., Carmell N., McDonald E., et al. (2015). Second generation tyrosine kinase inhibitors prevent disease progression in high-risk (high CIP2A) chronic myeloid leukaemia patients. Leukemia 29, 1514–1523. 10.1038/leu.2015.71 [DOI] [PubMed] [Google Scholar]
  104. Luque M., Cristóbal I., Sanz-Álvarez M., Santos A., Zazo S., Eroles P., et al. (2022). CIP2A as a key regulator for AKT phosphorylation has partial impact determining clinical outcome in breast cancer. J. Clin. Med. 11, 1610. 10.3390/jcm11061610 [DOI] [PMC free article] [PubMed] [Google Scholar]
  105. Ma L., Wen Z. S., Liu Z., Hu Z., Ma J., Chen X. Q., et al. (2011). Overexpression and small molecule-triggered downregulation of CIP2A in lung cancer. PLoS One 6, e20159. 10.1371/journal.pone.0020159 [DOI] [PMC free article] [PubMed] [Google Scholar]
  106. Ma W., Xiang Y., Yang R., Zhang T., Xu J., Wu Y., et al. (2019). Cucurbitacin B induces inhibitory effects via the CIP2A/PP2A/C-KIT signaling axis in t(8;21) acute myeloid leukemia. J. Pharmacol. Sci. 139, 304–310. 10.1016/j.jphs.2018.12.010 [DOI] [PubMed] [Google Scholar]
  107. Mathiasen D. P., Egebjerg C., Andersen S. H., Rafn B., Puustinen P., Khanna A., et al. (2012). Identification of a c-Jun N-terminal kinase-2-dependent signal amplification cascade that regulates c-Myc levels in ras transformation. Oncogene 31, 390–401. 10.1038/onc.2011.230 [DOI] [PubMed] [Google Scholar]
  108. Mercier C., Rousseau M., Geraldes P. (2020). Growth factor deregulation and emerging role of phosphatases in diabetic peripheral artery disease. Front. Cardiovasc Med. 7, 619612. 10.3389/fcvm.2020.619612 [DOI] [PMC free article] [PubMed] [Google Scholar]
  109. Monga J., Suthar S. K., Rohila D., Joseph A., Chauhan C. S., Sharma M. (2022). (+)-Cyanidan-3-ol inhibits epidermoid squamous cell carcinoma growth via inhibiting AKT/mTOR signaling through modulating CIP2A-PP2A axis. Phytomedicine 101, 154116. 10.1016/j.phymed.2022.154116 [DOI] [PubMed] [Google Scholar]
  110. Pallai R., Bhaskar A., Barnett-Bernodat N., Gallo-Ebert C., Nickels J. T., Jr., Rice L. M. (2015). Cancerous inhibitor of protein phosphatase 2A promotes premature chromosome segregation and aneuploidy in prostate cancer cells through association with shugoshin. Tumour Biol. 36, 6067–6074. 10.1007/s13277-015-3284-7 [DOI] [PubMed] [Google Scholar]
  111. Pallai R., Bhaskar A., Sodi V., Rice L. M. (2012). Ets1 and Elk1 transcription factors regulate cancerous inhibitor of protein phosphatase 2A expression in cervical and endometrial carcinoma cells. Transcription 3, 323–335. 10.4161/trns.22518 [DOI] [PMC free article] [PubMed] [Google Scholar]
  112. Pang X., Fu X., Chen S., Zhu X., Qi H., Li Y., et al. (2016). Overexpression of CIP2A promotes bladder cancer progression by regulating EMT. Clin. Transl. Oncol. 18, 289–295. 10.1007/s12094-015-1366-z [DOI] [PubMed] [Google Scholar]
  113. Peng B., Chai Y., Li Y., Liu X., Zhang J. (2015). CIP2A overexpression induces autoimmune response and enhances JNK signaling pathway in human lung cancer. BMC Cancer 15, 895. 10.1186/s12885-015-1899-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  114. Perrotti D., Neviani P. (2013). Protein phosphatase 2A: A target for anticancer therapy. Lancet Oncol. 14, e229–e238. 10.1016/s1470-2045(12)70558-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  115. Pippa R., Odero M. D. (2020). The role of MYC and PP2A in the initiation and progression of myeloid leukemias. Cells 9, 544. 10.3390/cells9030544 [DOI] [PMC free article] [PubMed] [Google Scholar]
  116. Posternak V., Cole M. D. (2016). Strategically targeting MYC in cancer. F1000Res 5, 408. 10.12688/f1000research.7879.1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  117. Qin S., Li J., Si Y., He Z., Zhang T., Wang D., et al. (2018). Cucurbitacin B induces inhibitory effects via CIP2A/PP2A/Akt pathway in glioblastoma multiforme. Mol. Carcinog. 57, 687–699. 10.1002/mc.22789 [DOI] [PubMed] [Google Scholar]
  118. Qu W., Li W., Wei L., Xing L., Wang X., Yu J. (2012). CIP2A is overexpressed in esophageal squamous cell carcinoma. Med. Oncol. 29, 113–118. 10.1007/s12032-010-9768-9 [DOI] [PubMed] [Google Scholar]
  119. Rantanen T., Kauttu T., Åkerla J., Honkanen T., Krogerus L., Salo J., et al. (2013). CIP2A expression and prognostic role in patients with esophageal adenocarcinoma. Med. Oncol. 30, 684. 10.1007/s12032-013-0684-7 [DOI] [PubMed] [Google Scholar]
  120. Remmerie M., Janssens V. (2019). PP2A: A promising biomarker and therapeutic target in endometrial cancer. Front. Oncol. 9, 462. 10.3389/fonc.2019.00462 [DOI] [PMC free article] [PubMed] [Google Scholar]
  121. Ren J., Li W., Yan L., Jiao W., Tian S., Li D., et al. (2011). Expression of CIP2A in renal cell carcinomas correlates with tumour invasion, metastasis and patients' survival. Br. J. Cancer 105, 1905–1911. 10.1038/bjc.2011.492 [DOI] [PMC free article] [PubMed] [Google Scholar]
  122. Routila J., Bilgen T., Saramäki O., Grénman R., Visakorpi T., Westermarck J., et al. (2016). Copy number increase of oncoprotein CIP2A is associated with poor patient survival in human head and neck squamous cell carcinoma. J. Oral Pathol. Med. 45, 329–337. 10.1111/jop.12372 [DOI] [PubMed] [Google Scholar]
  123. Ruvolo P. P. (2019). Role of protein phosphatases in the cancer microenvironment. Biochim. Biophys. Acta Mol. Cell Res. 1866, 144–152. 10.1016/j.bbamcr.2018.07.006 [DOI] [PubMed] [Google Scholar]
  124. Ruvolo P. P. (2016). The broken "off" switch in cancer signaling: PP2A as a regulator of tumorigenesis, drug resistance, and immune surveillance. BBA Clin. 6, 87–99. 10.1016/j.bbacli.2016.08.002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  125. Saafan H., Alahdab A., Michelet R., Gohlke L., Ziemann J., Holdenrieder S., et al. (2021). Constitutive cell proliferation regulating inhibitor of protein phosphatase 2A (CIP2A) mediates drug resistance to erlotinib in an EGFR activating mutated NSCLC cell line. Cells 10, 10040716. 10.3390/cells10040716 [DOI] [PMC free article] [PubMed] [Google Scholar]
  126. Sangodkar J., Farrington C. C., McClinch K., Galsky M. D., Kastrinsky D. B., Narla G. (2016). All roads lead to PP2A: Exploiting the therapeutic potential of this phosphatase. Febs J. 283, 1004–1024. 10.1111/febs.13573 [DOI] [PMC free article] [PubMed] [Google Scholar]
  127. Scarpa M., Singh P., Bailey C. M., Lee J. K., Kapoor S., Lapidus R. G., et al. (2021). PP2A-activating drugs enhance FLT3 inhibitor efficacy through AKT inhibition-dependent GSK-3β-mediated c-myc and pim-1 proteasomal degradation. Mol. Cancer Ther. 20, 676–690. 10.1158/1535-7163.Mct-20-0663 [DOI] [PMC free article] [PubMed] [Google Scholar]
  128. Shentu Y. P., Hu W. T., Zhang Q., Huo Y., Liang J. W., Liuyang Z. Y., et al. (2019). CIP2A-promoted astrogliosis induces AD-like synaptic degeneration and cognitive deficits. Neurobiol. Aging 75, 198–208. 10.1016/j.neurobiolaging.2018.11.023 [DOI] [PMC free article] [PubMed] [Google Scholar]
  129. Shi F., Ding Y., Ju S., Wu X., Cao S. (2014). Expression and prognostic significance of CIP2A in cutaneous malignant melanoma. Biomarkers 19, 70–76. 10.3109/1354750x.2013.871752 [DOI] [PubMed] [Google Scholar]
  130. Shi F. D., Zhang J. Y., Liu D., Rearden A., Elliot M., Nachtsheim D., et al. (2005). Preferential humoral immune response in prostate cancer to cellular proteins p90 and p62 in a panel of tumor-associated antigens. Prostate 63, 252–258. 10.1002/pros.20181 [DOI] [PubMed] [Google Scholar]
  131. Sipeky C., Gao P., Zhang Q., Wang L., Ettala O., Talala K. M., et al. (2018). Synergistic interaction of HOXB13 and CIP2A predisposes to aggressive prostate cancer. Clin. Cancer Res. 24, 6265–6276. 10.1158/1078-0432.Ccr-18-0444 [DOI] [PMC free article] [PubMed] [Google Scholar]
  132. Soo Hoo L., Zhang J. Y., Chan E. K. (2002). Cloning and characterization of a novel 90 kDa 'companion' auto-antigen of p62 overexpressed in cancer. Oncogene 21, 5006–5015. 10.1038/sj.onc.1205625 [DOI] [PubMed] [Google Scholar]
  133. Soofiyani S. R., Hejazi M. S., Baradaran B. (2017). The role of CIP2A in cancer: A review and update. Biomed. Pharmacother. 96, 626–633. 10.1016/j.biopha.2017.08.146 [DOI] [PubMed] [Google Scholar]
  134. Sumazaki M., Ogata H., Nabeya Y., Kuwajima A., Hiwasa T., Shimada H. (2021). Multipanel assay of 17 tumor-associated antibodies for serological detection of stage 0/I breast cancer. Cancer Sci. 112, 1955–1962. 10.1111/cas.14860 [DOI] [PMC free article] [PubMed] [Google Scholar]
  135. Sun L., Gao P. (2017). Reproducibility in cancer biology: Small molecules remain on target for c-myc. Elife 6, e22915. 10.7554/eLife.22915 [DOI] [PMC free article] [PubMed] [Google Scholar]
  136. Sung W. W., Wang Y. C., Lin P. L., Cheng Y. W., Chen C. Y., Wu T. C., et al. (2013). IL-10 promotes tumor aggressiveness via upregulation of CIP2A transcription in lung adenocarcinoma. Clin. Cancer Res. 19, 4092–4103. 10.1158/1078-0432.Ccr-12-3439 [DOI] [PubMed] [Google Scholar]
  137. Tan E. M. (2001). Autoantibodies as reporters identifying aberrant cellular mechanisms in tumorigenesis. J. Clin. Invest. 108, 1411–1415. 10.1172/jci14451 [DOI] [PMC free article] [PubMed] [Google Scholar]
  138. Tan E. M., Zhang J. (2008). Autoantibodies to tumor-associated antigens: Reporters from the immune system. Immunol. Rev. 222, 328–340. 10.1111/j.1600-065X.2008.00611.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  139. Tang M., Shen J. F., Li P., Zhou L. N., Zeng P., Cui X. X., et al. (2018). Prognostic significance of CIP2A expression in solid tumors: A meta-analysis. PLoS One 13, e0199675. 10.1371/journal.pone.0199675 [DOI] [PMC free article] [PubMed] [Google Scholar]
  140. Tang Q., Wang Q., Zeng G., Li Q., Jiang T., Zhang Z., et al. (2015). Overexpression of CIP2A in clear cell renal cell carcinoma promotes cellular epithelial-mesenchymal transition and is associated with poor prognosis. Oncol. Rep. 34, 2515–2522. 10.3892/or.2015.4217 [DOI] [PubMed] [Google Scholar]
  141. Tarek M. M., Yahia A., El-Nakib M. M., Elhefnawi M. (2021). Integrative assessment of CIP2A overexpression and mutational effects in human malignancies identifies possible deleterious variants. Comput. Biol. Med. 139, 104986. 10.1016/j.compbiomed.2021.104986 [DOI] [PubMed] [Google Scholar]
  142. Teng H. W., Yang S. H., Lin J. K., Chen W. S., Lin T. C., Jiang J. K., et al. (2012). CIP2A is a predictor of poor prognosis in colon cancer. J. Gastrointest. Surg. 16, 1037–1047. 10.1007/s11605-012-1828-3 [DOI] [PubMed] [Google Scholar]
  143. Tian Y., Chen H., Qiao L., Zhang W., Zheng J., Zhao W., et al. (2018). CIP2A facilitates the G1/S cell cycle transition via B-Myb in human papillomavirus 16 oncoprotein E6-expressing cells. J. Cell Mol. Med. 22, 4150–4160. 10.1111/jcmm.13693 [DOI] [PMC free article] [PubMed] [Google Scholar]
  144. Tseng L. M., Liu C. Y., Chang K. C., Chu P. Y., Shiau C. W., Chen K. F. (2012). CIP2A is a target of bortezomib in human triple negative breast cancer cells. Breast Cancer Res. 14, R68. 10.1186/bcr3175 [DOI] [PMC free article] [PubMed] [Google Scholar]
  145. Vaarala M. H., Väisänen M. R., Ristimäki A. (2010). CIP2A expression is increased in prostate cancer. J. Exp. Clin. Cancer Res. 29, 136. 10.1186/1756-9966-29-136 [DOI] [PMC free article] [PubMed] [Google Scholar]
  146. Vainonen J. P., Momeny M., Westermarck J. (2021). Druggable cancer phosphatases. Sci. Transl. Med. 13, eabe2967. 10.1126/scitranslmed.abe2967 [DOI] [PubMed] [Google Scholar]
  147. Velmurugan B. K., Wang H. K., Chung C. M., Lee C. H., Huang L. R., Yeh K. T., et al. (2019). CIP2A overexpression in Taiwanese oral cancer patients. Cancer Manag. Res. 11, 2589–2594. 10.2147/cmar.S201154 [DOI] [PMC free article] [PubMed] [Google Scholar]
  148. Ventelä S., Sittig E., Mannermaa L., Mäkelä J. A., Kulmala J., Löyttyniemi E., et al. (2015). CIP2A is an Oct4 target gene involved in head and neck squamous cell cancer oncogenicity and radioresistance. Oncotarget 6, 144–158. 10.18632/oncotarget.2670 [DOI] [PMC free article] [PubMed] [Google Scholar]
  149. Vogelstein B., Papadopoulos N., Velculescu V. E., Zhou S., Diaz L. A., Jr., Kinzler K. W. (2013). Cancer genome landscapes. Science 339, 1546–1558. 10.1126/science.1235122 [DOI] [PMC free article] [PubMed] [Google Scholar]
  150. Wang C. Y., Chao T. T., Chang F. Y., Chen Y. L., Tsai Y. T., Lin H. I., et al. (2014). CIP2A mediates erlotinib-induced apoptosis in non-small cell lung cancer cells without EGFR mutation. Lung Cancer 85, 152–160. 10.1016/j.lungcan.2014.05.024 [DOI] [PubMed] [Google Scholar]
  151. Wang H. W., Yang S. H., Huang G. D., Lin J. K., Chen W. S., Jiang J. K., et al. (2014). Temsirolimus enhances the efficacy of cetuximab in colon cancer through a CIP2A-dependent mechanism. J. Cancer Res. Clin. Oncol. 140, 561–571. 10.1007/s00432-014-1596-4 [DOI] [PubMed] [Google Scholar]
  152. Wang J., Huang T., Sun J., Yu Y., Liu Z., Li W., et al. (2014). CIP2A is overexpressed and involved in the pathogenesis of chronic myelocytic leukemia by interacting with breakpoint cluster region-Abelson leukemia virus. Med. Oncol. 31, 112. 10.1007/s12032-014-0112-7 [DOI] [PubMed] [Google Scholar]
  153. Wang J., Li W., Li L., Yu X., Jia J., Chen C. (2011). CIP2A is over-expressed in acute myeloid leukaemia and associated with HL60 cells proliferation and differentiation. Int. J. Lab. Hematol. 33, 290–298. 10.1111/j.1751-553X.2010.01288.x [DOI] [PubMed] [Google Scholar]
  154. Wang L., Gu F., Ma N., Zhang L., Bian J. M., Cao H. Y. (2013). CIP2A expression is associated with altered expression of epithelial-mesenchymal transition markers and predictive of poor prognosis in pancreatic ductal adenocarcinoma. Tumour Biol. 34, 2309–2313. 10.1007/s13277-013-0775-2 [DOI] [PubMed] [Google Scholar]
  155. Wang N., Zhou F., Guo J., Zhu H., Luo S., Cao J. (2018). Euxanthone suppresses tumor growth and metastasis in colorectal cancer via targeting CIP2A/PP2A pathway. Life Sci. 209, 498–506. 10.1016/j.lfs.2018.08.052 [DOI] [PubMed] [Google Scholar]
  156. Wang P., Qin J., Ye H., Li L., Wang X., Zhang J. (2019). Using a panel of multiple tumor-associated antigens to enhance the autoantibody detection in the immunodiagnosis of ovarian cancer. J. Cell Biochem. 120, 3091–3100. 10.1002/jcb.27497 [DOI] [PubMed] [Google Scholar]
  157. Wang X., Gao P., Wang M., Liu J., Lin J., Zhang S., et al. (2017). Feedback between E2F1 and CIP2A regulated by human papillomavirus E7 in cervical cancer: Implications for prognosis. Am. J. Transl. Res. 9, 2327–2339. [PMC free article] [PubMed] [Google Scholar]
  158. Wang X., Yang R., Wang Q., Wang Y., Ci H., Wu S. (2019). Aberrant expression of vasculogenic mimicry, PRRX1, and CIP2A in clear cell renal cell carcinoma and its clinicopathological significance. Med. Baltim. 98, e17028. 10.1097/md.0000000000017028 [DOI] [PMC free article] [PubMed] [Google Scholar]
  159. Wei L., Qu W., Sun J., Wang X., Lv L., Xie L., et al. (2014). Knockdown of cancerous inhibitor of protein phosphatase 2A may sensitize NSCLC cells to cisplatin. Cancer Gene Ther. 21, 194–199. 10.1038/cgt.2014.18 [DOI] [PubMed] [Google Scholar]
  160. Wei R., Ye X., Zhao Y., Jia N., Liu T., Lian W., et al. (2019). MicroRNA-218 inhibits the cell proliferation and migration in clear cell renal cell carcinoma through targeting cancerous inhibitor of protein phosphatase 2A. Oncol. Lett. 17, 3211–3218. 10.3892/ol.2019.9986 [DOI] [PMC free article] [PubMed] [Google Scholar]
  161. Westermarck J. (2018). Targeted therapies don't work for a reason; the neglected tumor suppressor phosphatase PP2A strikes back. Febs J. 285, 4139–4145. 10.1111/febs.14617 [DOI] [PubMed] [Google Scholar]
  162. Wiegering A., Pfann C., Uthe F. W., Otto C., Rycak L., Mäder U., et al. (2013). CIP2A influences survival in colon cancer and is critical for maintaining Myc expression. PLoS One 8, e75292. 10.1371/journal.pone.0075292 [DOI] [PMC free article] [PubMed] [Google Scholar]
  163. Williams A. P., Garner E. F., Waters A. M., Stafman L. L., Aye J. M., Markert H., et al. (2019). Investigation of PP2A and its endogenous inhibitors in neuroblastoma cell survival and tumor growth. Transl. Oncol. 12, 84–95. 10.1016/j.tranon.2018.09.011 [DOI] [PMC free article] [PubMed] [Google Scholar]
  164. Wu J., Ding M., Mao N., Wu Y., Wang C., Yuan J., et al. (2017). Celastrol inhibits chondrosarcoma proliferation, migration and invasion through suppression CIP2A/c-MYC signaling pathway. J. Pharmacol. Sci. 134, 22–28. 10.1016/j.jphs.2016.12.007 [DOI] [PubMed] [Google Scholar]
  165. Wu Y., Gu T. T., Zheng P. S. (2015). CIP2A cooperates with H-Ras to promote epithelial-mesenchymal transition in cervical-cancer progression. Cancer Lett. 356, 646–655. 10.1016/j.canlet.2014.10.013 [DOI] [PubMed] [Google Scholar]
  166. Xie C., Kim H. J., Haw J. G., Kalbasi A., Gardner B. K., Li G., et al. (2011). A novel multiplex assay combining autoantibodies plus PSA has potential implications for classification of prostate cancer from non-malignant cases. J. Transl. Med. 9, 43. 10.1186/1479-5876-9-43 [DOI] [PMC free article] [PubMed] [Google Scholar]
  167. Xing M. L., Lu Y. F., Wang D. F., Zou X. Y., Zhang S. X., Yun Z. (2016). Clinical significance of sCIP2A levels in breast cancer. Eur. Rev. Med. Pharmacol. Sci. 20, 82–91. [PubMed] [Google Scholar]
  168. Xu P., Huang Q., Xie F., Xu X. L., Shao F. (2013). Increased expression of CIP2A in cholangiocarcinoma and correlation with poor prognosis. Hepatogastroenterology 60, 669–672. [PubMed] [Google Scholar]
  169. Xu P., Xu X. L., Huang Q., Zhang Z. H., Zhang Y. B. (2012). CIP2A with survivin protein expressions in human non-small-cell lung cancer correlates with prognosis. Med. Oncol. 29, 1643–1647. 10.1007/s12032-011-0053-3 [DOI] [PubMed] [Google Scholar]
  170. Xu P., Yao J., He J., Zhao L., Wang X., Li Z., et al. (2016). CIP2A down regulation enhances the sensitivity of pancreatic cancer cells to gemcitabine. Oncotarget 7, 14831–14840. 10.18632/oncotarget.7447 [DOI] [PMC free article] [PubMed] [Google Scholar]
  171. Xue Y., Wu G., Wang X., Zou X., Zhang G., Xiao R., et al. (2013). CIP2A is a predictor of survival and a novel therapeutic target in bladder urothelial cell carcinoma. Med. Oncol. 30, 406. 10.1007/s12032-012-0406-6 [DOI] [PubMed] [Google Scholar]
  172. Yang X., Qu K., Tao J., Yin G., Han S., Liu Q., et al. (2018). Inhibition of CIP2A attenuates tumor progression by inducing cell cycle arrest and promoting cellular senescence in hepatocellular carcinoma. Biochem. Biophys. Res. Commun. 495, 1807–1814. 10.1016/j.bbrc.2017.11.124 [DOI] [PubMed] [Google Scholar]
  173. Yang X., Zhang Y., Liu H., Lin Z. (2016). Cancerous inhibitor of PP2A silencing inhibits proliferation and promotes apoptosis in human multiple myeloma cells. Biomed. Res. Int. 2016, 6864135. 10.1155/2016/6864135 [DOI] [PMC free article] [PubMed] [Google Scholar]
  174. Yi F., Ni W., Liu W., Bai J., Li W. (2013). Expression and biological role of CIP2A in human astrocytoma. Mol. Med. Rep. 7, 1376–1380. 10.3892/mmr.2013.1357 [DOI] [PubMed] [Google Scholar]
  175. Yin J., Chen D., Luo K., Lu M., Gu Y., Zeng S., et al. (2019). Cip2a/miR-301a feedback loop promotes cell proliferation and invasion of triple-negative breast cancer. J. Cancer 10, 5964–5974. 10.7150/jca.35704 [DOI] [PMC free article] [PubMed] [Google Scholar]
  176. Yu G., Liu G., Dong J., Jin Y. (2013). Clinical implications of CIP2A protein expression in breast cancer. Med. Oncol. 30, 524. 10.1007/s12032-013-0524-9 [DOI] [PubMed] [Google Scholar]
  177. Yu H. C., Chen H. J., Chang Y. L., Liu C. Y., Shiau C. W., Cheng A. L., et al. (2013). Inhibition of CIP2A determines erlotinib-induced apoptosis in hepatocellular carcinoma. Biochem. Pharmacol. 85, 356–366. 10.1016/j.bcp.2012.11.009 [DOI] [PubMed] [Google Scholar]
  178. Yu H. C., Hung M. H., Chen Y. L., Chu P. Y., Wang C. Y., Chao T. T., et al. (2014). Erlotinib derivative inhibits hepatocellular carcinoma by targeting CIP2A to reactivate protein phosphatase 2A. Cell Death Dis. 5, e1359. 10.1038/cddis.2014.325 [DOI] [PMC free article] [PubMed] [Google Scholar]
  179. Yu N., Zhang T., Zhao D., Cao Z., Du J., Zhang Q. (2018). CIP2A is overexpressed in human endometrioid adenocarcinoma and regulates cell proliferation, invasion and apoptosis. Pathol. Res. Pract. 214, 233–239. 10.1016/j.prp.2017.11.011 [DOI] [PubMed] [Google Scholar]
  180. Yu X. J., Zhao Q., Wang X. B., Zhang J. X., Wang X. B. (2016). Gambogenic acid induces proteasomal degradation of CIP2A and sensitizes hepatocellular carcinoma to anticancer agents. Oncol. Rep. 36, 3611–3618. 10.3892/or.2016.5188 [DOI] [PubMed] [Google Scholar]
  181. Zhai M., Cong L., Han Y., Tu G. (2014). CIP2A is overexpressed in osteosarcoma and regulates cell proliferation and invasion. Tumour Biol. 35, 1123–1128. 10.1007/s13277-013-1150-z [DOI] [PubMed] [Google Scholar]
  182. Zhang H. F., Qin J. J., Ren P. F., Shi J. X., Xia J. F., Ye H., et al. (2016). A panel of autoantibodies against multiple tumor-associated antigens in the immunodiagnosis of esophageal squamous cell cancer. Cancer Immunol. Immunother. 65, 1233–1242. 10.1007/s00262-016-1886-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  183. Zhang J., Guo X., Jin B., Zhu Q. (2022). Editorial: Tumor-associated antigens and their autoantibodies, from discovering to clinical utilization. Front. Oncol. 12, 970623. 10.3389/fonc.2022.970623 [DOI] [PMC free article] [PubMed] [Google Scholar]
  184. Zhang J. Y., Tan E. M. (2010). Autoantibodies to tumor-associated antigens as diagnostic biomarkers in hepatocellular carcinoma and other solid tumors. Expert Rev. Mol. Diagn 10, 321–328. 10.1586/erm.10.12 [DOI] [PMC free article] [PubMed] [Google Scholar]
  185. Zhang J. Y., Wang X., Peng X. X., Chan E. K. (2002). Autoantibody responses in Chinese hepatocellular carcinoma. J. Clin. Immunol. 22, 98–105. 10.1023/a:1014483803483 [DOI] [PubMed] [Google Scholar]
  186. Zhang X., Xu B., Sun C., Wang L., Miao X. (2015). Knockdown of CIP2A sensitizes ovarian cancer cells to cisplatin: An in vitro study. Int. J. Clin. Exp. Med. 8, 16941–16947. [PMC free article] [PubMed] [Google Scholar]
  187. Zhang Y., Huang P., Liu X., Xiang Y., Zhang T., Wu Y., et al. (2018). Polyphyllin I inhibits growth and invasion of cisplatin-resistant gastric cancer cells by partially inhibiting CIP2A/PP2A/Akt signaling axis. J. Pharmacol. Sci. 137, 305–312. 10.1016/j.jphs.2018.07.008 [DOI] [PubMed] [Google Scholar]
  188. Zhang Y., Wang X. (2020). Targeting the Wnt/β-catenin signaling pathway in cancer. J. Hematol. Oncol. 13, 165. 10.1186/s13045-020-00990-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  189. Zhao Q., Zhao M., Parris A. B., Xing Y., Yang X. (2016). Genistein targets the cancerous inhibitor of PP2A to induce growth inhibition and apoptosis in breast cancer cells. Int. J. Oncol. 49, 1203–1210. 10.3892/ijo.2016.3588 [DOI] [PMC free article] [PubMed] [Google Scholar]
  190. Zhao S., Gao X., Zang S., Li Y., Feng X., Yuan X. (2017). MicroRNA-383-5p acts as a prognostic marker and inhibitor of cell proliferation in lung adenocarcinoma by cancerous inhibitor of protein phosphatase 2A. Oncol. Lett. 14, 3573–3579. 10.3892/ol.2017.6603 [DOI] [PMC free article] [PubMed] [Google Scholar]
  191. Zheng Z., Qiao Z., Chen W., Gong R., Wang Y., Xu L., et al. (2016). CIP2A regulates proliferation and apoptosis of multiple myeloma cells. Mol. Med. Rep. 14, 2705–2709. 10.3892/mmr.2016.5553 [DOI] [PubMed] [Google Scholar]
  192. Zhu Z., Wei Z. (2021). CIP2A silencing alleviates doxorubicin resistance in MCF7/ADR cells through activating PP2A and autophagy. Clin. Transl. Oncol. 23, 1542–1548. 10.1007/s12094-021-02616-7 [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Frontiers in Genetics are provided here courtesy of Frontiers Media SA

RESOURCES